

COVID-19: A promising cure for the global panic

Balachandar Vellingiri^{1,*,#}, Kaavya Jayaramayya^{2,#}, Mahalaxmi Iyer², Arul Narayanasamy³, Vivekanandhan Govindasamy⁴, Bupesh Giridharan^{5,6}, Singaravelu Ganesan⁷, Anila Venugopal¹, Dhivya Venkatesan¹, Harsha Ganesan¹, Kamarajan Rajagopalan¹, Pattanathu K.S.M Rahman⁸, Ssang-Goo Cho⁹, Nachimuthu Senthil Kumar¹⁰, Mohana Devi Subramaniam¹¹

¹Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore – 641 046, Tamil Nadu, India.

²Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore – 641 043, Tamil Nadu, India.

³Disease Proteomics Laboratory, Department of Zoology, Bharathiar University, Coimbatore – 641 046, Tamil Nadu, India.

⁴Farmer's Bio Fertilizers and Organics, Coimbatore – 641 029, Tamil Nadu.

⁵Virology Laboratory, Central Research and Development Wing, Sree Balaji Medical College and Hospital (SBMCH), Bharath University, (BIHER), Chromepet, Chennai-600044, Tamil Nadu, India.

⁶Department of Forest Science, Central University of Nagaland, Lumami, Zunhebeto.

⁷Department of Zoology, Thiruvalluvar University, Vellore – 632115.

⁸Deploy Lead - Centre for Enzyme Innovation, Office No: 6.06, King Henry Building School of Biological Science, University of Portsmouth, Portsmouth – PO1 2DY, UK.

⁹Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul, South Korea.

¹⁰Department of Biotechnology, Mizoram University (A Central University), Aizawl – 796 004, Mizoram, India

¹¹Department of Genetics and Molecular Biology, Vision Research Foundation, Chennai – 600 006, India.

#Authors have equal contribution

***Corresponding Author:**

Dr. Vellingiri Balachandar

Assistant Professor and Group Leader - Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore – 641 046, Tamil Nadu, India

Mobile: +91 9994999924; Office: +91 422 2422514; +91 422 2422222; Fax: +91 422 2422387;

E-mail: geneticbala@buc.edu.in; geneticbala@yahoo.co.in

Acknowledgements:


The author Dr. VB would like to thank Bharathiar University for providing the necessary infrastructure facility and the Science and Engineering Research Board (SERB) (ECR/2016/001688), Government of India, New Delhi for providing necessary help in carrying out this review process in the Neuroinvasive section of the manuscript and Dr.SMD would like to thank the Science and Engineering Research Board (SERB) (ECR/2018/000718), Government of India, New Delhi for providing necessary help in carrying out this review process. The Authors wish to thank the Advanced Level State Biotech Hub (BT/04/NE/2009 Dt.29.082014), Mizoram University, Aizawl sponsored by the Department of Biotechnology (DBT), New Delhi, Government of India for providing the infrastructural support and facilities. P Pattanathu.K.S.M.Rahman thanks Research England for funding support through the Expanding Excellence in England (E3) scheme. The Authors would also like to thank Mr.T.Navaneethakrishnan (Indian Traditional Medicinal plant - based practitioner) Mettupalayam, India for providing valuable support for the preparation of the subtopic based on Indian medicinal plants.

Funding:

This work was supported by the Science and Engineering Research Board (SERB), Government of India [ECR/2016/001688]; the Science and Engineering Research Board (SERB), Government of India [ECR/2018/000718]; the Advanced Level State Biotech Hub (BT/04/NE/2009 Dt.29.082014); the Expanding Excellence in England (E3) scheme.

Conflicts of Interest:

The authors have no conflicting interest.



Highlights

- SARS-COV-2 is structurally similar to SARS-COV
- The mechanism of SARS-COV-2 in the host cell may be comparable to SARS-COV
- SARS-CoV-2 invade the immune and nervous system
- There is an urgent need for novel treatment options for COVID-19
- Indian medicinal plants are likely to be potential drugs for the treatment of COVID-19

1 **Abstract**

2 The novel Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, which
3 is the causative agent of a potentially fatal disease that is of great global public health
4 concern. The outbreak of COVID-19 is wreaking havoc worldwide due to inadequate
5 risk assessment regarding the urgency of the situation. The COVID-19 pandemic has
6 entered a dangerous new phase. When compared with SARS and MERS, COVID-19
7 has spread more rapidly, due to increased globalization and adaptation of the virus in
8 every environment. Slowing the spread of the COVID-19 cases will significantly
9 reduce the strain on the healthcare system of the country by limiting the number of
10 people who are severely sick by COVID-19 and need hospital care. Hence, the recent
11 outburst of COVID-19 highlights an urgent need for therapeutics targeting SARS-
12 CoV-2. Here, we have discussed the structure of virus; varying symptoms among
13 COVID-19, SARS, MERS and common flu; the probable mechanism behind the
14 infection and its immune response. Further, the current treatment options, drugs
15 available, ongoing trials and recent diagnostics for COVID-19 have been discussed.
16 We suggest traditional Indian medicinal plants as possible novel therapeutic
17 approaches, exclusively targeting SARS-CoV-2 and its pathways.

18 **Keywords:** Coronavirus disease 2019 (COVID-19); SARS-CoV-2; Mechanism of
19 action; Therapeutic approach; Indian traditional medicine.

20 **Abbreviations:**

21
22 ACE2: Angiotensin-Converting Enzyme 2; ACE2-Fc: Angiotensin Converting
23 Enzyme 2 Fc; ADAM17: ADAM metallopeptidase domain 17; ARDS: Acute
24 respiratory distress syndrome; ASC: Apoptosis-associated speck-like protein
25 containing a CARD; CNS: Central Nervous System; COVID-19: Coronavirus disease
26 2019; ER: Endoplasmic reticulum; ExoN: exoribonuclease; FDA: Food and Drug
27 Administration; FP: internal fusion protein; HCoV: Human coronavirus; HIV: Human
28 immunodeficiency virus; JAK-STAT: Janus kinase/signal transducer and activator of
29 transcription; JNK: c-Jun N- terminal kinase; MCP-1: Monocyte chemoattractant
30 protein-1; MERS: Middle East respiratory syndrome; MERS-CoV: Middle East
31 respiratory syndrome coronavirus; MHV: Mouse hepatitis virus; mRNA: Messenger

RNA; NF- κ B: Nuclear Factor kappa-light-chain-enhancer of activated B-cells; NIH: National Institutes of Health; NLRP3: Nod-like receptor protein 3; ORF: open reading frame; PHEIC: Public Health Emergency of International Concern; PHEV: Porcine Hemagglutinating Encephalomyelitis Virus; RBD: receptor binding domain; RBM: receptor binding motif; RCT: randomized controlled treatment; RdRp: RNA dependent RNA polymerase; RNA: Ribonucleic acid; ROS: Reactive oxygen species; RTC: replicase-transcriptase complex; SARS: Severe acute respiratory syndrome; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; TM: transmembrane; TMPRSS11a: Transmembrane serine protease 11a; TNF β : Tumor necrosis factor β ; TRAF3: TNF receptor associated factor 3; TRS: transcriptional regulatory sequence; WHO: World Health Organization

1. Introduction

The novel coronavirus disease 2019 (COVID-19), caused by the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is in the midst of worldwide panic and global health concern since December 2019. As of March 26th, 2020, the World Health Organization (WHO) has reported that 4,16,686 and 18,589 death cases have been confirmed worldwide, and it has spread to 197 countries (WHO, 2020a). With this emerging battle against this deadly virus, the WHO has strategized to interrupt human-human contact, isolate patients at early stages, identify and reduce transmission from the animal source, address crucial mysteries about the virus and accelerate research, communicate information correctly to the public and minimize the social and economic impact. At this juncture, it is tremendously vital to understand the basic mechanism of the virus to develop specific drugs. Currently, it has been established that SARS-CoV-2 shares sequence homology with the SARS-CoV and a bat coronavirus (Gorbalenya, 2020). Despite its similarity to SARS-CoV, its transmission efficiency and diagnostic methods are rather different. The distinguishing factor is probably the nucleotide changes in the spike (S) protein and its receptor-binding domain (RBD) (Kannan et al., 2020; Coutard et al., 2020; Wan et al., 2020). Currently, the treatments include Lopinavir/Ritonavir and supportive care, as this is primarily dependent on the severity of the illness. From a research

standpoint, various drugs are being developed at an extremely quick pace and new targets are being identified every day, and also numerous drugs are also undergoing clinical trials. Researches are very curious about how to provide the best protection to the public before a vaccine can be made available (Balachandar et al., 2020). Indian medicinal herbs are a promising field for treatment of various illnesses (Gomathi et al., 2020). Ayurveda and Siddha practices originated in India and are still widely used among the Indian population. By identifying certain phytochemicals, it is possible to effectively characterize medicinal herbs that could help to alleviate the infection. Hence, by repurposing the Indian medicinal plants, more innovative treatment options can be penned down for their role in defeating this viral transmission. At a time of worldwide anxiety, it is imperative to find long term solutions to prevent the transmission of such pandemics. So, it's time for all the citizens to join hands together to fight against coronavirus by practicing self-hygiene and social distancing (Balachandar et al., 2020). In this review, the structure, immunological influence, mechanism of action of the SARS-CoV-2 infection in the human host cell, the availability of disease-specific drugs, ongoing clinical trials, recent diagnostics and the potential use of certain Indian medicinal herbs for the effective treatment of COVID-19 has been discussed. Through this review, we suggest that the Indian traditional medicinal herbs may be a beneficial step to combat viruses like the SARS-CoV-2.

2. A brief overview of coronavirus

Coronaviruses, having a total of 39 species under the broad realm of Riboviria, belong to the family Coronaviridae, suborder Cornidovirineae and order Nidovirales (Gorbalenya et al., 2020). All the SARS-CoV fall under the species *Severe acute respiratory syndrome-related coronavirus* and genus *Beta-coronavirus*.

88 Most of the species under this head are enzootic and only a few of these species infect
89 humans (Schoeman and Fielding, 2019). Currently, seven human CoVs (HCoVs)
90 have been confirmed. Specifically, they are named as Human coronavirus *NL63*
91 (HCoV-NL63) and Human coronavirus 229E (HCoV-229E), which belong to the
92 *alpha-coronavirus* genus; whereas Human coronavirus OC43 (HCoV-OC43), Human
93 coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and Middle East respiratory
94 syndrome coronavirus (MERS-CoV), belong to the *beta-coronavirus* genus. HCoV-
95 229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 strains of coronavirus cause
96 mild respiratory diseases in humans. The SARS-CoV-2 is a zoonotic virus that
97 belongs to the Coronaviridae family that can infect human and several animal species
98 (Lu et al., 2020). The SARS-CoV-2 belongs to the subgenus *Sarbecovirus* and mostly
99 resembles a bat coronavirus, with which it shares 96.2% sequence homology (Chan et
100 al., 2020a). Currently, it is thought that SARS-CoV-2 has been introduced to human
101 by an unidentified intermediary animal and then it has spread from human-to-human.

102 Human coronaviruses are predominantly concomitant with upper respiratory
103 tract illnesses ranging from mild to moderate including common cold. Most of the
104 people may be infected with one or more of these viruses at some point in their
105 lifetime (Killerby et al., 2018). The SARS-CoV and MERS-CoV are the two major
106 causes of severe pneumonia in human (Song et al., 2019). A comparative analysis of
107 the symptoms among COVID-19, SARS, MERS and common flu has been explained
108 (Table.1). The world observed the sudden emergence of COVID-19 in 2019. The
109 exact origin of the virus, continues to remain as a mystery, to researchers worldwide.
110 Investigations need to be carried out to pinpoint the exact source of infection. The
111 WHO, on February 11, 2020, officially named the viral disease COVID-19 (Jiang, et
112 al., 2020; Guarner, 2020). The Coronavirus Study Group of the International

Committee on Taxonomy of Viruses named the new pathogen as SARS-CoV-2 (Gorbalenya, 2020). The predecessor SARS-CoV first emerged in 2002. During its course of infection from 2002 to 2003, 774 deaths were recorded out of the 8000+ infections spread across 37 countries (Peiris et al., 2004). This was closely followed by the emergence of MERS-CoV at Saudi Arabia in 2012, which caused 858 deaths among the 2494 known infected cases (Zaki et al., 2012). Similar to its antecedents, the SARS-CoV-2 appeared in December 2019 from the animal kingdom and spread to human populations. The COVID-19 is known to show symptoms slowly over an incubation period of around 2 weeks. During this time the virus replicates in the upper and lower respiratory tract, forming lesions (Chan et al., 2020b). The general symptoms observed in the infected individuals are fever, cough, dyspnoea and lesion in the lungs (Huang et al., 2020). In the advanced stage, the symptoms of this virus show pneumonia which progresses to severe pneumonia and acute respiratory distress syndrome (ARDS) which results in to the need for life-support to sustain the patient's life (Heymann and Shindo, 2020).

3. Structural Assembly of SARS-CoV-2 Virus

The SARS-CoV-2 belongs to the largest family of the RNA viruses and its genome ranges from 27 to 32 kilobases in size (~125 nanometers or 0.125 microns). It is a single stranded enveloped RNA virus which possess a positive-sense RNA genome also known as (+ssRNA) with a 5'-cap structure and 3'-poly-A tail (Chen, 2020). The viruses belonging to this category, have a few common characteristics that are applicable to SARS-CoV-2 as well. The virus has four important structural proteins which are (E) the envelope protein (M) the membrane protein (S) the spike protein and (N) the nucleocapsid protein, which are required to regulate the function and viral structure (Schoeman and Fielding, 2019). Among these four proteins the

most important ones are N and S, where the former one helps the virus to develop the capsid and the entire viral structure appropriately and the later one helps in the attachment of virus to the host cells (Siu et al., 2008; Walls et al., 2020). The S protein has three major sections which are, the large ectodomain, a single-pass transmembrane anchor and a short intracellular tail. These play a major role in anchoring the host cells. Among these sections the ectodomain has two subunits which are, the S1 receptor-binding subunit and S2 the membrane fusion subunit. These subunits are in the clove-trimeric or crown structure which is the reason coronavirus (corona = crown) got its name (Zumla et al., 2016).

It has been reported that the SARS-CoV and SARS-CoV-2 have similar kind of receptors, especially the receptor binding domain (RBD) and the receptor binding motif (RBM) in the viral genome (Yin and Wunderink, 2018; Zhang et al., 2020; Tai et al., 2020). During the SARS infection, the RBM of the S protein gets directly attached to the Angiotension-Converting Enzyme 2 (ACE2) in the human or the host cells (Phan, 2020). The ACE2 protein is expressed in various organs of the human body mainly in the lungs, kidney and intestine, the prime targets of the coronavirus (Zhao et al., 2020). The ACE1 and ACE2 have gained recognition as significant regulators of the physiology and pathology of the reproductive system (Pan et al., 2013). Although, due to the novel nature of the virus, no study has proven that it will reduce men's fertility or sexual potency but medics in Wuhan have suggested the likelihood that the disease can affect the production of sperm leading to low sperm count and the formation of male sex hormones (low libido). In addition, SARS-CoV-2 infects host cell through ACE2 receptors leading to COVID-19 related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system (Zheng et al., 2020).

Interestingly, it has also been proposed that SARS-CoV-2 mechanism of action in infection of humans is similar to the SARS. It has been reported that the RBM of the SARS-CoV-2 has a major amino acid residue (Gln493) that favours the attachment and fusion of the viral S protein with virus into the ACE2 protein of the human cell especially the one present in the lungs which results in respiratory infections in humans (Zhao et al., 2020; Yin and Wunderink, 2018). An illustration about the structure and binding of S protein to ACE2 has been depicted (Fig.1). The simplest and most direct approach to combat SARS-CoV-2 would be to neutralize the virus from entering cells as this has been utilized in previous viruses of its kind (Walker and Burton, 2018). The key advantage here is the host ACE2 protein does not change, so there is no fear about advantageous mutations that may hinder drug development (Karakus et al., 2020). These findings suggest that an in-depth knowledge about the receptors and its targets and basis of viral replication would be a stepping stone to find a remedy for the SARS-CoV-2 infection.

4. Replication of SARS-CoV-2

After the SARS-CoV-2 virus has entered the human host cells, the next step for its survival is its RNA replication. The viral RNA replication is the most unusual and critical step carried out by the virus for its survival inside the host body. The tools that are required for the process of replication are open reading frames (ORFs), two replicase genes (rep1a and rep1ab), a slippery sequence (5'-UUUAAAC-3') and two polyproteins (pp1a and pp1ab). Both these polyproteins contain the most important proteins of the virus that are the Nsp proteins (Nsp1-11 and Nsp1-16), these proteins are a common occurrence in these virus types (Baranov et al., 2005). Recently, it has been found that, the Nsp 15 protein not only has a vital role in replication but also attacks the immune system of the host during viral replication (Youngechang et al.,

2020). Further these Nsp proteins (Nsp1/2, Nsp2/3 and Nsp3/4) assemble to form the replicase-transcriptase complex (RTC) which creates an environment inside the host body suitable for RNA synthesis and replication. Also, these Nsps have various roles in RNA replication of the virus. Nsp12 codes for the RNA-dependent RNA polymerase (RdRP) domain, Nsp13 is encrypted with RNA helicase domain and RNA 5'-triphosphase, Nsp14 encodes exoribonuclease (ExoN) which helps in replication conformity and finally Nsp16 encodes 2'-O-methyltransferase activity. These evidences prove that Nsp protein has a vital role in keeping the virus alive inside the host body by promoting basic synthesis, replication and translation.

The process of replication in the SARS-CoV-2 similar to SARS-CoV virus is multifaceted and needs more understanding (Fehr and Perlman, 2015; Zhang et al., 2020). For replication, the genomic RNA contains a 5' end region that has the untranslated leader (L) sequence with the transcription regulation sequence (TRS) present at the descending region of the genome (Brian and Baric, 2005). The replicase gene encoded enzymes uses the negative RNA genome as a template to develop a few sets of small, overlapping messenger RNA (mRNA) molecules that further gets translated into the structural proteins *viz.* (N, M, E and S protein) also known as the building block for the production of new viral particles inside the host body, while the positive stranded RNA genome is used as a template to produce the negative strand. During the replication process inside the human host, the N protein of the virus binds to the genome while the M protein is associated with the membranes of the endoplasmic reticulum (ER). Further with the help of Nsp proteins the RNA gets assembled into a helical twisted structure and buds into the ER lumen. Viral progenies are transferred to the cell membranes by the Golgi bodies and exocytosed into the extracellular space of the human host cell environment. These mechanisms were

discovered in the preceding viruses and may have a pivotal role in SARS-CoV-2 as well (Brian and Baric, 2005; de Haan and Rottier, 2005). From the replication process of the SARS-CoV-2 it is evident that targeting Nsp proteins could enable us to develop a strategy to overcome this viral infection. Other than replication, other pathways associated with the virus can also be targeted for drug development.

5. SARS-CoV-2- proposed mechanism

SARS-CoV-2 shares homology with the SARS-CoV but the rate of transmission and infectivity of the SARS-CoV-2 has been remarkable; this accelerated spreading rate may be due to a gain of function mutation, making this novel virus different from the SARS-CoV virus. These changes found in SARS-CoV-2 include, an absent 8a, longer 8b and shorter 3b segments and different Nsp 2 and 3 proteins (Wu et al., 2020; Xu et al., 2020). Nsp 2 of SARS-CoV-2 consists of mutation that is probably associated with the ability of the virus to be more contagious (Angeletti et al., 2020). In addition, the orf8 and orf10 proteins are also different in SARS-CoV-2. It may be beneficial to understand the biological function of these proteins. Further, it has been found that more pathogenic viruses contain a furin like cleavage site in the S protein, which is not present in SARS-CoV but present in the SARS-CoV-2 (Coutard et al., 2020). This may be the reason for increased virulence of SARS-CoV-2. Moreover, SARS-CoV-2 binds the same receptor as SARS-CoV, namely, ACE2 with much higher strength; this could be the reason for the increased transmission rate and its capacity to affect other species with such ease. The S protein has S1 on its N terminal and S2 at its C terminal, and the RBD is present at the S1 region. The S2 domain of the S protein consists of the fusion protein, a second proteolytic site (S2'), followed by an internal fusion peptide (FP) and two heptad-repeat domains preceding the transmembrane domain (TM) and

internal FP is identical between SARS-CoV-2 and SARS-CoV (Coutard et al., 2020). From previous studies it was suggested that SARS-CoV-2 might have a similar mechanism as like SARS-CoV to enter the host cell.

The SARS-CoV-2 like other beta-coronaviruses undergoes a few steps to enter into and affect the host cell. SARS-CoV-2 binds to same ACE2 receptor present in the respiratory epithelium and alveoli of the lungs (Liu et al., 2020). In SARS-CoV, upon binding to the receptor, proteases are recruited to cleave the S protein into S1 and S2 domains. This cleavage induces a conformational change that activates S2, this is followed by the insertion of the FP into the membrane and membrane fusion occurs facilitating the entry of the virus into the cell. Since the nucleotides are conserved in RBD binding motif that is associated with ACE2, it is possible that SARS-CoV-2 utilizes the same mechanism as well. Once the virus enters the cell, ACE2 gets cleaved and shed by ADAM17 into the extra membrane space. Reduced ACE2 has been known to be concomitant with alveoli injury and increases pulmonary vascular permeability (Li and Clercq, 2020). This could be due to the conversion of angiotensin I to angiotensin II by ACE2, which is a negative regulator of the renin-angiotensin pathway. Angiotensin II stimulated ATIR results in the lung pathology associated with respiratory distress (Li and Clercq, 2020). Once the virus translates its proteins in the cell, the ORF3a protein is produced and codes for a Ca^{2+} ion channel that is similar to SARS-CoV and SARS-CoV-2. It interacts with TRAF3 and activates the transcription of the NF-kB pathway, resulting in the transcription of the pro-IL-1B gene (Siu et al., 2019), ORF3a along with TRAF3 also recruits the inflammasome complex. This complex consists of NLRP3, ASC and caspase 1. A second signal such as Ca^{2+} influx, caspases activation, ROS production and mitochondrial damage converts pro-IL-1B to IL-1B and results in cytokine production. Another, ORF8b

protein also activates the inflammasome pathway through NLRP3, and this protein is longer in SARS-CoV-2 (Shi et al., 2019). The extra nucleotides present in this virus need to be further studied to figure out if that has caused an added advantage. The E protein forming an ion channel, is also conserved in the two viruses and is involved in the overproduction of cytokines through the NLRP3 inflammasome pathway (Nieto-Torres et al., 2015). All these pathways combined together cause a cytokine storm resulting in respiratory distress a common symptom of COVID-19. Another pathway involved in SARS-CoV includes the JNK pathway; which is activated by ORF3a, ORF3b and ORF7a which may lead to an increased production of pro-inflammatory factors, escalating lung damage (Liu et al., 2014). The JNK pathway can also be considered as a target for SARS-CoV-2 as it also involves the proteins that are analogous in both viruses.

During the infection of the virus, the most important part is the interaction with the host cell nucleases. It is possible that SARS-CoV-2 may use proteases similar to SARS-CoV such as TMPRSS11a, Trypsin, Plasmin, Cathepsin L and Furin in the cleavage of the spike protein for the virus to enter the cell. These proteases can be used as targets to reduce the symptoms of COVID-19 as proteasomal inhibitors used for HIV treatment are being used in treatment of COVID-19 (Fig.2). A target for the COVID-19 may be advantageous to understand the involvement of the immune system in COVID-19, to explore the possibility of developing specific vaccines for it, as elucidated for previous viruses (Simmons et al., 2013).

6. SARS-CoV-2 and the immune system

The HCoVs generally are very long (30,000 bp) positive-sense single-stranded RNA viruses. Two groups of protein characterize HCoVs; the structural proteins, and non-structural proteins such as RNA dependent RNA polymerase (RdRp) (nsp12)

288 (Elfiky, 2020). Coronaviruses such as SARS and MERS are particularly adept at
289 evading immune detection and dampening immune responses. Its not yet clear how
290 SARS-CoV-2 affects the immune system. During viral infection, host factors elicits
291 immune response against the viruses. T cells, particularly CD4+ and CD8+ play a
292 significant antiviral role to combat the pathogens and elevate the risk of developing
293 autoimmunity/inflammation (Cecere et al., 2012). The CD4+T cells advance the
294 production of viral- specific antibodies by activating T cell- dependent B cells.
295 However, CD8+ T cells are cytotoxic and kill virus infected cells. The CD8+ T cells
296 account for about 80% of total inflammatory cells in the pulmonary interstitium in
297 SARS-CoV infected patients and play a critical role in clearing coronaviruses in
298 infected cells and inducing immune injury (Maloir et al., 2018). In addition, T helper
299 cells make proinflammatory cytokines via NF-kB signaling (Manni et al., 2014). The
300 cytokines, IL-17 recruit monocytes and neutrophils to the infection site showing
301 inflammation and activates other downstream cascades of cytokines and chemokines,
302 including IL-1, IL-6, IL-8, IL-21, TNF- β , and MCP-1(Bunte and Beikler, 2019). It
303 was observed that, T cell apoptosis was induced by a novel BH3-like region located in
304 the C-terminal cytosolic domain of SARS-CoV protein mediated by Bcl-xL (Yang et
305 al., 2005). From the experimental evidences it was shown that T cell response to S
306 protein and other structural proteins (including the M and N proteins) is long-lasting,
307 persistent and provides evidence for designing new drugs and vaccines for SARS-
308 CoV-2 composed of viral structural proteins, which can induce dominant, effective,
309 and long-term memory cell responses against the virus. However, earlier studies have
310 also reported a crucial role of both CD8+ and CD4+ T cells in SARS-CoV clearance
311 (Chen et al., 2010), while Janice et al. (2012) also observed that development of
312 SARS-CoV specific neutralizing antibodies requires CD4+ T helper cells. Moreover,

the ACE2 protein fused to a human immunoglobulin G Fc domain (ACE2-Fc) of SARS-CoV-2 patients may have the benefits of a traditional neutralizing antibody which could be used as a treatment for the infection. Ultimately, there will be a need for clinical trials to delineate any specific side effects of ACE2-Fc treatment (Kruse, 2020). Therefore ACE2-Fc might play an important role in the treatment of SARS-CoV-2, if the function of ACE2-Fc is inhibited (Kruse, 2020). These immunological studies show how crucial it is to understand the basics of the immune responses in these viruses, so these immune cells can be induced to further attack the virus with increased specificity. Besides the immune system, scientists have also found a possible involvement of the COVID-19 in the nervous system.

7. Neuroinvasion of HCoV-229E:

The COVID-19 are not always confined to the respiratory tract, but they also invade the Central Nervous System (CNS) to induce neurological diseases. Coronaviruses with such potential are the beta-coronaviruses, including SARS-CoV (Glass et al., 2004), MERS-CoV (Li et al., 2016), HCoV-229E (Talbot et al., 1994), HCoV-OC43 (Dubé et al., 2018), mouse hepatitis virus (MHV) (Zhou et al., 2017), and Porcine Hemagglutinating Encephalomyelitis Virus (PHEV) (Mengeling et al., 1972). According to previous study, coronaviruses may initially invade peripheral nerves and enter the CNS via the synaptic route, where this trans-synaptic transfer has been documented in HEV67 and avian bronchitis virus (Matsuda, et al., 2004). The first coronavirus found to invade the porcine brain was HEV 67N, and it shares >91% homology with HCoV-OC43 (Li et al., 2016). Therefore, the neuroinvasive propensity has been demonstrated as a common feature of coronaviruses. Since there is a high similarity between SARS-CoV and SARS-CoV-2, it is quite likely that SARS-CoV-2 may also possess an analogous potential. Based on an epidemiological

survey, the first symptom is dyspnea which occurs in 5 days, followed by hospital admission at 7 days, and intensive care at 8 days for COVID-19 (Wang et al., 2020). This latency period is enough for the virus to enter and destroy the medullary neurons. A possible mechanism about the entry of SARS-CoV-2 inside the CNS has been illustrated (Fig.3). Similarly, Mathew (2020) stated that the symptoms might attribute to respiratory disease is due to the inability of air to get into the lungs, that might actually be the defects in respiration controlled by the nervous system. It has been reported that some COVID-19 patients showed neurologic signs, including headache (about 8%), nausea and vomiting (1%). As the neuroinvasion of SARS-CoV-2 is accompanied by respiratory failure in COVID-19 patients, the entry of the virus into the CNS must be prevented. As an emerging virus, awareness of the possible entry of SARS-CoV-2 into the CNS is significant for prevention and treatment. It is also important to find effective antiviral drugs that can cross the blood-brain barrier (Li et al., 2020). Therefore, more innovative approaches are required to detect this viral infection at an earlier period.

8. Recent diagnostic techniques

During the SARS and MERS outbreaks effective diagnostic tools were developed for accurate detection. Although, useful at that time, it is now essential to develop specific tests for COVID-19. The viral nucleic acid detection is primarily used in SARS-CoV-2 diagnosis (Wang et al., 2020). CDC has recommended the collection of upper respiratory nasopharyngeal (NP) swabs for the diagnostic tests (CDC, 2020). The CDC detection assay targets the N region and consists of one test for beta-coronaviruses and two unique probes for SARS-CoV-2. The Charité algorithm comprises of probes for E protein and RA-dependent RNA polymerase (RdRp). Once both are positive, the sample is again tested against specific SARS-

CoV-2 RdRp (Loeffelholz and Tang, 2020). Contrastingly, the E protein with RdRp was also detecting SARS-CoV, and so, these assays can be used to test for the SARS-CoV-2 when there are no traces of SARS-CoV (Cordes and Heim, 2020). When the commercially available Real Star kit, Virus +Rox Vial kit and Super Script III One-step RT-PCR System with Platinum TaqDNA Polymerase were compared for their efficiency, the RealStar Kit did not have any unwanted signals and exceeded the other two in its performance (Konrad et al., 2020). These methods can also be compromised due to inadequate sample volume, inaccuracies in methods of testing, not collecting samples at the appropriate time window, and contamination. Similar issues have been identified as potential problems that may diminish the precision of the tests (Lippi et al., 2020). Moreover, these tests are also expensive, hence cheaper alternatives have been developed to track the symptoms of COVID-19 using smart-phone surveillance (Dorigatti et al., 2020). Imaging techniques can also be utilized as a diagnostic method in COVID-19. Additionally, chest CT scans have been facilitated to detect lung abnormalities in this SARS-CoV-2 infection (Shi et al., 2020; Xu et al., 2020). Abnormalities in the CT scans can be concomitant with disease progression and prognosis. But, not all the cases can be perfectly detected with CT scans (Lei et al., 2020). Therefore, it is essential to conduct molecular tests and consider travel history and clinical symptoms of the patient as well. As there are an upsurge of infected people, more efficient, quicker and cheaper diagnostic tools must be developed to effectively identify infected individuals. Hence, the integrated approach of imaging and molecular diagnosis would help in screening and treating COVID -19 effectively. In order to design these specific drugs, it is important to understand the current strategies used to treat this novel COVID-19

9. Classification of Pipeline Drugs

389 Though the number of affected individuals is constantly on the rise, there are
390 no FDA approved drugs for COVID-19 yet. At present, treatment provided to the
391 affected individuals are mainly symptom based, and the seriously ill individuals are
392 provided with organ support (Jin et al., 2020; Zumla et al., 2020). It is necessary to
393 invest time and effort in identifying vaccines and drugs for this novel virus. Since the
394 development of drugs specific for COVID -19 will take at least a few months drugs
395 which have been proven to be safe for humans can be repurposed to treat this disease.
396 The vast majority of the drugs used for treatment worldwide falls under any of the
397 following classification of drugs.

398 **9.1. Antiviral drugs** - Drugs under this category usually follow either of the
399 following three mechanisms in the virus-viral replication inhibition, ion channel
400 inhibition and serine protease inhibition. Commercially available antiviral drugs
401 mostly target the four major groups of viruses: human immunodeficiency virus (HIV),
402 herpes, hepatitis and influenza (Razonable, 2011). Earlier outbreak episodes of viral
403 infections like SARS-CoV and MERS-CoV as well as hemorrhagic fever viruses like
404 Ebola were treated with this category of drugs (De Clercq, 2007).

405 **9.2. Antimalarial drugs** - These drugs also fall under three categories based on their
406 mode of action aryl amino-alcohol compound, antifolate compound and artemisinin.
407 Most of these drugs are eliminated gradually from the body remaining for long
408 periods of time after intake. A disadvantage of this drug is that antimalarial drug
409 resistance develops for any drugs under this category (Edwin et al., 2019).

410 **9.3. Anti-HIV drugs** - These drugs are classified into different categories based on
411 their targets reverse transcription, retro-transcription, proteolytic processing, viral-cell
412 fusion, co-receptors interactions and incorporation of proviral DNA into the host
413 genome. Drugs that fall in these categories have been approved by the FDA (Food

and Drug Administration) and are now officially used for the treatment of HIV (De Clercq, 2009).

9.4. Anti-inflammatory drugs - Huge inflammatory response is observed in COVID-19. Anti-inflammatory drugs especially JAK-STAT inhibitors, used against rheumatoid arthritis, may be effective against elevated levels of cytokines and useful in inhibiting viral infection. According to recent study, an inflammatory drug, baricitinib when used in combination with anti-viral drugs like Remdesivir, increases the potential of the drug to reduce viral infection (Stebbing et al., 2020).

9.5. Monoclonal antibodies - The virus is known to enter the host cells by binding the S protein to ACE2 receptors. By developing neutralizing antibodies against the receptors, there is a high possibility for reducing the severity of the disease (Zheng and Song, 2020). Currently, only a handful of drugs have been approved for use against SARS-CoV-2.

10. Clinically Used Drugs

Even before the declaration of COVID-19 as a pandemic by WHO, there was an immense lack of disease specific drugs. Being a rapidly spreading virus, it is essential to provide timely treatment for the affected individuals (Zumla et al., 2016). A list of potential drugs is provided in Table 2 and a few of the commonly used drugs are discussed below;

10.1. Ribavirin - Ribavirin is also a broad-spectrum drug whose therapeutic potential was uncovered during 1972. This antiviral drug is used in the treatment of hepatitis C. It is usually used in combination with interferon α (IFN). This drug, approved by the FDA, competes for the active site of RdRp. Ribavirin scored 109.5 μM of half maximal concentration against SARS-CoV-2 (Elfiky, 2020).

10.2. Sofosbuvir - This drug is also an FDA approved drug against NS5B and acts as a nucleotide polymerase inhibitor used for the treatment of hepatitis C. It was used in combination with interferon or RBV. This drug was previously used for the treatment of Zika virus (Cheema et al., 2019).

10.3. Lopinavir/Ritonavir - Lopinavir is a protease inhibitor which targets the HIV virus. It was identified by 1998 and approved by the FDA by 2000. This drug prevents the formation of viral proteins by disrupting the proteolytic processing by mimicking its structure as a peptide cleaved by HIV protease. This drug along with another flu drug oseltamivir was reported to result in complete recovery after showing signs of COVID-19 related pneumonia (Wu et al., 2020).

10.4. Remdesivir (anti-viral peptide) - This particular drug is an adenosine nucleotide analog, which was used in treatments against Ebola, SARS-CoV and MERS-CoV. It is a promising and potential drug which causes premature termination by entering the nascent viral RNA (Warren et al., 2016). Currently, it is undergoing clinical trials for Ebola treatment (Mulangu et al., 2019). Another recent study has shown that Remdesivir scored 0.77 μM at half maximal concentration against COVID-19 and blocked viral infection (Wang et al., 2020).

10.5. Chloroquine - This drug, classified as an anti-malarial drug, has shown potential in the treatment of avian influenza A (Yan et al., 2013). Chloroquine also has shown to have anti-viral as well as immune modulating properties. This drug also showed 1.13 μM at half maximal concentration against SARS-CoV-2 and blocked viral infection by increasing the endosomal pH required for viral fusion (Wang et al., 2020; Vincent et al., 2005).

10.6. Favipiravir - This drug is also a broad spectrum anti-viral drug which has obtained approval from Shenzhen Health Commission for treating COVID-19 patients (Wu et al., 2020).

10.7. Ongoing Clinical Trials

Currently, there are numerous companies that have applied for clinical trials to repurpose existing drugs as well as to develop vaccines and drugs to fight against the fast spreading COVID-19 (Rudra, et al., 2017). In the case of repurposing the existing drugs, randomized controlled treatment (RCT) are being carried out by various biotechnological companies as well as research organizations such as National Institutes of Health (NIH), USA to identify disease specific drugs. The major drugs undergoing clinical trials that have the potential to treat this viral infection (Table 3). More research may be required in traditional medicine to utilize them in the treatment of COVID-19.

10. Importance of Indian Medicine

Indian traditional medicinal systems are considered as one of the oldest treatments in human history and it plays an important role in encountering global health care needs (Ravishankar and Shukla, 2007). Traditional Indian medicinal practices include Ayurveda, Siddha, Unani and Yoga, Naturopathy and Homoeopathy, which are successfully practiced for treating various diseases (Gomathi et al., 2020). These practices came into existence 5000 years ago, and these systems have been witnessed and scripted in ancient literature.

Traditional Indian medicine use plants, minerals and animal products for curing human diseases. Traditional knowledge regarding the plant sources and their usage are essential to use them accurately and for the right condition (Tabuti et al., 2003) About 25,000 plant based formulations have been used in folk remedies in

486 Indian medicine (Pundarikakshudu and Kanaki, 2019). Recently, the total number of
487 Indian medicinal plants was estimated to be around 3000, yet, traditional practitioners
488 use around 8000 different species for their practice (Pundarikakshudu and Kanaki,
489 2019). Traditional medicines are generally ignored in research and development of
490 modern drugs since their translational potentials are often underestimated. Although
491 these medicines are ambiguous, there are wide contexts for their usage in non-
492 Western medical technology (Yuan et al., 2016). A single herb may contain many
493 phytochemical constituents that function alone or in combination with other
494 compounds to produce the desired pharmacological effect (Parasuraman et al., 2014).
495 Due to their use in traditional medicine, many plant molecules have been studied and
496 subsequently modulated into drugs for various diseases (Li-Weber, 2009; Fabricant
497 and Farnsworth, 2001). The search for new compounds with antiviral activity has
498 often been unsatisfactory due to viral resistance along with viral latency and recurrent
499 infection in immune-compromised patients (Sumithira et al., 2012). Among antiviral
500 therapeutic methods, the majority of them are non-specific for viruses (Jiang et al.,
501 2015). The advancements in developing antiviral agents are the major focus in medical
502 research. The antiviral effects of medicinal plants have played a tremendous role at
503 different stages of viral growth (Akram et al., 2018). Plant derived pharmacological
504 formulations marked a major contribution for viral infections (Cragg et al., 1997).
505 Based on the availability of suitable, efficient and rapid bioassay systems, the
506 antiviral compounds have been used for rapid screening from plant extracts and
507 fractions (Scior et al., 2012). Instead of synthetic antiviral drugs, medicinal plants
508 deliver basic raw materials for important antiviral drugs (Moghadamtousi et al.,
509 2015). Synthetic drugs have been replaced by medicinal plants, as life-saving drugs
510 (Gurib-Fakim, 2006) in various viral diseases. Unfortunately, the usage of these

medication have been passed down to generations by word of mouth and most of them have been lost over time, due to the lack of proper documentation. Research on these herbs and medicinal plants may help to promote their usage in clinical settings to prevent or treat various illnesses. Since many Indian medicinal plants exhibit antiviral, anti-inflammatory and antioxidant properties, it may be favorable to consider them for the treatment of COVID-19. It is clear that standard clinical trials should be carried out to scientifically prove its efficacy.

11. Indian medicinal plants and their possible effect on COVID-19

Since ancient times, Indian herbs have been used as a treatment and preventive strategy for several diseases, including respiratory viral infections. The benefit of using these herbs in viral respiratory infections is to build immune stimulating and inflammation modulating effects of manage the immune system. Holistic approach of AYUSH systems of medicine gives focus on prevention through lifestyle modification, dietary management, prophylactic interventions for improving the immunity and simple remedies based on presentation of the symptoms (AYUSH, 2020). Indian preventive and prophylactic medicinal plants recommended by AYUSH for COVID-19 (Table 4). Also, other studies on coronavirus using medicinal plants are rather minimal in India, a study has shown anti-mouse coronaviral activity (a surrogate of SARS-CoV) by the plants *Indigofera tinctoria* (AO), *Vitex trifolia*, *Gymnema sylvestre*, *Abutilon indicum*, *Leucas aspera*, *Cassia alata*, *Sphaeranthus indicus*, *Clitoria ternatea*, *Clerodendrum inermis* Gaertn, *Pergularia daemia* and *Evolvulus alsinoides* in Tamil Nadu (Vimalanathan et al., 2009). Among them *Vitex trifolia* and *Sphaeranthus indicus* have been found to reduce inflammatory cytokines using the NF- κ B pathway, a pathway that has been implicated in respiratory distress in SARS-CoV (Alam et al., 2002; Srivastava et al., 2015). *Clitoria ternatea* has been

536 identified as a metalloproteinase inhibitor, ADAM17, a metalloproteinase that is
 537 involved in ACE shredding can be targeted using this plant, as ACE-2 shredding has
 538 been associated with an increased formation of viruses (Maity et al., 2012). The plants
 539 *Glycyrrhiza glabra* (Nourazarian, 2015) and *Allium sativum* (Keyaerts et al., 2007)
 540 have been known to target the viral replication of SARS-CoV, arising as promising
 541 candidates against SARS-CoV-2. *Clerodendrum inerme Gaertn* , another herb has
 542 been found to have the potential to inactivate the viral ribosome, this can be further
 543 investigated for its utility as a drug targeting SARS-CoV-2 protein translation
 544 (Olivieri et al., 1996). Similarly, *Strobilanthes Cusia* (Tsai et al., 2020) blocked the
 545 viral RNA genome synthesis and induced papain like protease activity targeting the
 546 HCoV. In Asia, Himalayan forests are abundantly flourished with rich medicinal plant
 547 species and a study has documented the presence of ethnomedicinal plants against
 548 bronchitis (Amber et al., 2017). The study screened the antiviral plant properties
 549 against bronchitis, which showed that *Hyoscyamus niger*, *Justicia adhatoda* and
 550 *Verbascum thapsus* reduced infections caused by influenza viruses. The molecular
 551 mechanism by which these plants target influenza virus can be studied to understand
 552 if they attack any molecules overlapping between SARS-CoV-2 and the Influenza
 553 viruses. *Hyoscyamus niger* was found to be a bronchodilator and also had inhibitory
 554 effects on Ca^{2+} channel (Gilani et al., 2008). This could be used to target the orf3a
 555 Ca^{2+} channels that trigger various downstream pathways upon viral infection. Most
 556 importantly, various medicinal plants have shown inhibitory effects against ACE, and
 557 these include *Coriandrum sativum* (Hussain et al., 2018), *Boerhaavia diffusa*, *Cynara*
 558 *scolymus* , *Coscinium fenestratum*, *Punicagranatum* *Cassia occidentalis*
 559 and *Embeliaribes*. Among them, *Punicagranatum* showed a competitive mode of
 560 action while the rest were non-specific inhibitors (Khan and Kumar, 2019; Prathapan

et al., 2013). These plants need to be studied further to examine their actual effects on the entry of SARS-CoV-2 into the host cell. One of the tropical species in the Acanthaceae family, *Andrographis paniculata* (kalmegh) present in South Asia has a strong treating capacity of viral respiratory infections in Ayurvedic and other medicinal systems (Yarnell, 2018; Arora et al., 2011; Coon and Ernst, 2004). It was noted that *Andrographis paniculata* suppressed increased NOD-like receptor protein 3 (NLRP3), caspase-1, and interleukin-1 β molecules which are extensively involved in the pathogenesis of SARS-COV and likely SARS-CoV-2 as well (Liu et al., 2020). *Salacia oblonga* (He et al., 2011) another plant from Tamil Nadu has also displayed suppressive effects on angiotensin II, AT1 signal, which was related to lung damage. Many plants have also shown inhibitory actions towards HIV proteases, these plants can be promising drugs for COVID-19. They include, *Acacia nilotica* (Shanti, 2016), *Eugenia jambolana* (Otake et al., 1995), *Euphorbia granulate* (Shanti, 2016). Some plants like *Ocimum sanctum* (Rege and Chowdhary, 2014), *Ocimumkilim* and *scharicum* (Thayil Seema and Thyagarajan, 2016), *Solanum nigrum* (Yu, 2004), *Vitex negundo* (NAIR, 2012) have been known to target the reverse transcriptase activity of HIV and can be studied for activity against SARS-CoV-2 as well. Further, *Sambucus ebulus* (Ganjhu et al., 2015) has been known to inhibit the activity of enveloped viruses and can also be used to target this virus. These medicinal plants can be used to ameliorate the symptoms of COVID-19. Though many medicinal plants have been identified, a lot of research has to be carried out for the development of drug specific to SARS-CoV-2. Therefore, it is important to explore the effect of these prescribed traditional medicines on SARS-CoV-2 (Table.5). Various Indian medicinal plants that have been widely used for respiratory diseases have been included (Supplementary table.1).

12. COVID-19- The global challenges

COVID-19 has emerged as the most dangerous pandemic threat through-out the globe since its outbreak during December 2019. It has become a big challenge for the researchers and virologist to find a solution for this deadly disease. This is attributed to the fact that COVID-19 is a viral infection that has been known to have the fastest frequency of recombination or replication in its positive strand resulting in the quick formation of new progeny viral cells inside the host cells. It has also been reported that SARS-CoV-2 has a high rate of mutagenesis and changes in structure, which has created a barrier for both investigations of the disease and therapeutic regimens (American society for microbiology, 2020). Recently, few researchers have identified that the SARS-CoV-2 has mainly two types of strains, which are the 'L' and 'S' strains. Among these strains the L strain is more common and may have evolved from the S strain; additionally, this L strain has a higher rate of replication inside the human host cell, which has resulted in the escalation of the infection in limited time. Hence, it has become a big challenge to analyze the condition and offer therapy at the short time available. Due to the high mutation rate, it has been harder to understand the genomic organization and host interaction of the virus (Habibzadeh and Stoneman, 2020).

The genomic structure of the virus is not the only factor that presents a great challenge to research, its ability to adapt and survive in different environmental conditions make it nearly impossible to identify its mode of survival. It has been earlier reported that the SARS virus can survive at 4°C with a humidity rate of 20%. The first outbreak of the SARS-CoV-2 was during the peak of winter, where the environmental temperature was around 2°C to 10°C. But since then the virus has infected people and survived in countries of completely different climatic conditions,

making its demographic association hard to predict. The health care professionals and equipment are limited and are unable to handle the vast number of patients who are infected. Moreover, some of the individuals who are infectious are asymptomatic and continue to travel or gather in social surroundings infecting more people. These factors pose a challenge for scientists, health-care professional and government officials to handle and contain the condition. Government officials in all countries continue to make efforts to minimize human contact by facilitating country wide shutdowns of public places as well as various steps have been initiated to ensure the safety of the people, like social distancing and self-quarantine which limits our social interactions. This will reduce the risk of spreading the COVID-19 to people by breaking the transmission chain and the influx of new COVID-19 cases in a given time period (Balachandar et al., 2020).

13. Concluding Remarks

Over the past few decades, there was an urge to discover the root cause of coronavirus infections not only in animals but in humans as well. Currently, COVID-19 has emerged as the most intense and petrifying viral infection to be handled by the human race. According to WHO (2020b), major concern among public health throughout the world and many countries have taken precautionary measures against the virus, and Government officials in all countries continue to make efforts to minimize human contact by facilitating countrywide shutdowns of public places as well as various steps have been initiated to ensure the safety of the people, like social distancing and self-quarantine which limits our social interactions (Balachandar et al, 2020). This will reduce the risk of spreading the COVID-19 to people by breaking the transmission chain and the influx of new COVID-19 cases in a given time period. Total confirmed cases throughout the world are 4,16,686 and total number of

confirmed deaths are 18,589 (WHO, 2020a) as on 26th March 26, 2020 and in India 581 cases (ICMR, 2020) have been identified to be positive for this COVID-19 and 11 death cases in India as on 25th March 2020 (20:00 IST). More cases are likely to be identified in the coming days in India. This increase in infection was mainly due to the ability of this virus to recombine, mutate, block the immune system of the host cells and infect multiple species as well as cell types. Moreover, discovering the gene pool of SARS-CoV-2 may help accelerate the production of drugs and vaccines. Further, analyzing and understanding the role of non-structure and accessory proteins encrypted in this virus will aid us in understanding its mechanism of action. Also, acquiring an in-depth framework of its unique RNA replication process will enable us to find a breakthrough point to understand the host immunological response. Our review suggests the importance of a few Indian medicinal plants that have been used for several decades in the treatment of various respiratory conditions. It highlights the pathways that the plant-based medicines may target to reduce the disease burden. Thus, proactive investments in researches based on Indian medicinal plant derived vaccines or drugs to treat COVID-19 would emerge as a source of light to overcome this fatal infection.

14. Recommendations

The cases reported in many parts of China and the outbreaks involve large numbers in Italy, USA, Spain and Germany; hence travel restrictions and quarantine measures have been placed in severely affected areas. The spectrum of symptoms associated with COVID-19 ranges from difficulties in breathing and other respiratory conditions to critical conditions including SARS, kidney failure and sometimes even death. Individuals are likely to be infected by others who have been inflicted with the virus. The disease can spread from person to person via small droplets from nose or

661 mouth when a person with COVID-19 coughs or exhales. These particles in the air,
662 settle on surfaces in the environment further infecting people who breathe these
663 particles or touch these places and then touch their body parts. Hence, it is important
664 to stay more than 1 meter (3 feet) away from a person who is sick (WHO, 2020c).
665 Reports suggest that older persons and persons with pre-existing medical conditions
666 (such as high blood pressure, heart disease, lung disease, cancer or diabetes) appear to
667 develop serious illness more often than others, also pregnant women with the
668 infection had did not pass the infection to their unborn babies (Wu and McGoogan,
669 2020; Chen et al., 2020). Also it has been reported that some of the Asian populations
670 are more susceptible to acquire this COVID-19 infection when compared to the other
671 races populations (Xu, 2020). Following are the protective measures given by WHO
672 (2020d),

- 673 a) Wash hands completely using an alcohol-based hand sanitizer will kill the virus,
- 674 b) Avoid touching eyes, nose and mouth when outside.
- 675 c) Be updated about the virus.
- 676 d) Avoid travelling or gathering in crowded places.
- 677 e) Women with infants are encouraged to breastfeed their babies to enhance their
678 immunity.

679 WHO is coordinating efforts to develop vaccines and medicines to prevent and treat
680 COVID-19 (WHO, 2020d). National Institutes of Health (NIH), has mentioned that
681 SARS-CoV-2 could survive for up to three hours maximum as aerosols to a maximum
682 of three days on surfaces. Slowing the spread of the COVID-19 cases will
683 significantly reduce the strain on the healthcare system of the country by limiting the
684 number of people who are severely sick by COVID-19 and need hospital care. It will
685 also give researchers more time to develop the vaccine against COVID-19. So, it's

time for all the citizens to join hands together to fight against coronavirus by practicing self-hygiene and social distancing.

Authors Contribution:

Conceptualization: BV; KJ; IM; SMD; Data curation: KJ, IM, SMD, BV, AV; DV, VG, BG; Funding acquisition: BV, SMD; Investigation: IM, KJ; Project administration: BV; Resources: VG, NSK, SGC, SG, BG, BR, AN, PR; Supervision: BV, SGC, NSK, SG, VG, AN; Roles/Writing - original draft: KJ, IM, SMD, BV, AV; DV; HG, KR.

References

- Akamatsu, H., Komura, J., Asada, Y., Niwa, Y., 1991. Mechanism of anti-inflammatory action of glycyrrhizin: effect on neutrophil functions including reactive oxygen species generation. *Planta Med.* 57,119-121. <https://doi.org/10.1055/s-2006-960045>.
- Akram, M., Tahir, I.M., Shah, S.M.A., Mahmood, Z., Altaf, A., Ahmad, K., Munir, N., Daniyal, M., Nasir, S., Mehboob, H., 2018. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. *Phytother. Res.* 32, 811–822. <https://doi.org/10.1002/ptr.6024>.
- Alam, G., Wahyuono, S., Ganjar, I.G., Hakim, L., Timmerman, H., Verpoorte, R., 2002. Tracheospasmolytic activity of viteosin-A and vitexicarpin isolated from *Vitex trifolia*. *Planta Med.* 68, 1047–1049. <https://doi.org/10.1055/s-2002-35650>.
- Amber, R., Adnan, M., Tariq, A., Mussarat, S., 2017. A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms. *J. Pharm. Pharmacol.* 69, 109–122. <https://doi.org/10.1111/jphp.12669>.
- American Society of Microbiology (2020), <https://asm.org/PressReleases/2020/COVID-19-Resources>. (Accessed 25 March 2020).
- Angeletti, S., Benvenuto, D., Bianchi, M., Giovanetti, M., Pascarella, S., Ciccozzi, M., 2020. COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. *J. Med. Virol.* 2020, 1-5. <https://doi.org/10.1002/jmv.25719>.
- Arora, R., Chawla, R., Marwah, R., Arora, P., Sharma, R., Kaushik, V., Goel, R., Kaur, A., Silambarasan, M., Tripathi, R., 2011. Potential of complementary and alternative medicine in preventive management of novel H1N1 flu (Swine flu) pandemic: thwarting potential disasters in the bud. *Evid. Based Complement. Alternat. Med.* 2011,1-16. <https://doi.org/10.1155/2011/586506>.
- Arun, L. B., Arunachalam, A. M., Arunachalam, K. D., Annamalai, S. K., Kumar, K. A., 2014. In vivo anti-ulcer, anti-stress, anti-allergic, and functional properties of Gymnemic Acid Isolated from *Gymnema sylvestre* R Br. *BMC Compl. Alternative. Med.* 14, 70. <https://doi.org/10.1186/1472-6882-14-70>.

- Ministry of Ayush, Government of India, 2020. Homeopathy for prevention of Coronavirus infections. <https://pib.gov.in/PressReleasePage.aspx?PRID=1600895>
- Balachandar, V., Mahalaxmi, I., Kaavya, J., Vivek, G., Ajithkumar, S., Arul, N., Singaravelu, G., Nachimuthu, S.K., Mohana Devi, S. 2020. COVID-19: Emerging protective measures. *Eur. Rev. Med. Pharmacol.* 24 (In Press).
- Baranov, P.V., Henderson, C.M., Anderson, C.B., Gesteland, R.F., Atkins, J.F., Howard, M.T., 2005. Programmed ribosomal frameshifting in decoding the SARS-CoV genome. *Virology*. 332, 498–510. <https://doi.org/10.1016/j.virol.2004.11.038>.
- Beaucourt, S., Vignuzzi, M., 2014. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. *Molecular basis of ribavirin resistance. Curr. Opin. Virol.* 8, 10–15. <https://doi.org/10.1016/j.coviro.2014.04.011>.
- Beck, B.R., Shin, B., Choi, Y., Park, S., Kang, K., 2020. Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. *bioRxiv*. <https://doi.org/10.1101/2020.01.31.929547>.
- Bertram, S., Dijkman, R., Habjan, M., Heurich, A., Gierer, S., Glowacka, I., Welsch, K., Winkler, M., Schneider, H., Hofmann-Winkler, H., 2013. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. *J. Virol.* 87, 6150–6160. <https://doi.org/10.1128/JVI.03372-12>.
- Blanchard, J.E., Elowe, N.H., Huitema, C., Fortin, P.D., Cechetto, J.D., Eltis, L.D., Brown, E.D., 2004. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. *Chem. Biol.* 11, 1445–1453. <https://doi.org/10.1016/j.chembiol.2004.08.011>.
- Brian, D., Baric, R., 2005. Coronavirus genome structure and replication. *Curr. Top. Microbiol. Immunol.* 287, 1–30. https://doi.org/10.1007/3-540-26765-4_1.
- Bunte, K., Beikler, T., 2019. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. *Int. J. Mol. Sci.* 20, 3394. <https://doi.org/10.3390/ijms20143394>.
- Cao, Y., 2020. Suggestion Using Alcohol Vaporization or Nebulization Inhalation Therapy for Pneumonitis Caused by Coronavirus. Available at SSRN 3545744.
- Cecere, T.E., Todd, S.M., LeRoith, T., 2012. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it?. *Viruses*. 4, 833–846. <https://doi.org/10.3390/v4050833>.
- Centers for Disease Prevention and Control (CDC), 2020. <https://www.cdc.gov/coronavirus/2019-ncov/index.html> (Accessed on 25 March 2020).
- Chan, J.F. W., Kok, K. H., Zhu, Z., Chu, H., To, K. K. W., Yuan, S., Yuen, K. Y., 2020a. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg. Microbes Infect.* 9, 221–236.
- Chan, J.F.W., Yip, C.C.Y., To, K.K.W., Tang, T.H.C., Wong, S.C.Y., Leung, K.H., Fung, A.Y.F., Ng, A.C.K., Zou, Z., Tsoi, H.W., 2020b. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction

775 assay validated in vitro and with clinical specimens. *J. Clin. Microbiol.*
 776 <https://doi.org/10.1128/JCM.00310-20>.
 777 Cheema, S.U.R., Rehman, M.S., Hussain, G., Cheema, S.S., Gilani, N., 2019.
 778 Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of
 779 hepatitis C genotype 1 & 3 in patients undergoing hemodialysis-a prospective
 780 interventional clinical trial. *BMC nephrol.* 20, 438.
 781 <https://doi.org/10.1186/s12882-019-1631-4>.
 782 Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D.,
 783 Gong, Q., 2020. Clinical characteristics and intrauterine vertical transmission
 784 potential of COVID-19 infection in nine pregnant women: a retrospective
 785 review of medical records. *The Lancet.* 395, 809-
 786 815. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
 787 Chen, J., 2020. Pathogenicity and transmissibility of 2019-nCoV—a quick overview
 788 and comparison with other emerging viruses. *Microbes. Infect.* 22, 69-71.
 789 <https://doi.org/10.1016/j.micinf.2020.01.004>.
 790 Chen, J., Lau, Y.F., Lamirande, E.W., Paddock, C.D., Bartlett, J.H., Zaki, S.R.,
 791 Subbarao, K., 2010. Cellular immune responses to severe acute respiratory
 792 syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice:
 793 CD4+ T cells are important in control of SARS-CoV infection. *J. Virol.* 84,
 794 1289–1301. <https://doi.org/10.1128/JVI.01281-09>.
 795 Chou, C.Y., Chien, C.H., Han, Y.S., Prebenda, M.T., Hsieh, H.P., Turk, B., Chang,
 796 G.G., Chen, X., 2008. Thiopurine analogues inhibit papain-like protease of
 797 severe acute respiratory syndrome coronavirus. *Biochem. Pharmacol.* 75,
 798 1601–1609. <https://doi.org/10.1016/j.bcp.2008.01.005>.
 799 Chu, C., Cheng, V., Hung, I., Wong, M., Chan, KH, Chan, KS, Kao, R., Poon, L.,
 800 Wong, C., Guan, Y., 2004. Role of lopinavir/ritonavir in the treatment of
 801 SARS: initial virological and clinical findings. *Thorax* 59, 252–256.
 802 <https://doi.org/10.1136/thorax.2003.012658>.
 803 Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr, H., 2003.
 804 Treatment of SARS with human interferons. *The Lancet.* 362, 293–294.
 805 [https://doi.org/10.1016/s0140-6736\(03\)13973-6](https://doi.org/10.1016/s0140-6736(03)13973-6).
 806 Comper, W., 2005. Charged polysaccharides resistant to lysosomal degradation
 807 during kidney filtration and renal passage and their use to treat or prevent
 808 infection by coronaviruses. <https://europepmc.org/article/pat/wo2004093888>.
 809 Contini, A., 2020. Virtual screening of an FDA approved drugs database on two
 810 COVID-19 coronavirus proteins. *Chem Rxiv.* [https://doi.org/10.26434/chemrxiv.](https://doi.org/10.26434/chemrxiv.11847381.v1)
 811 11847381.v1.
 812 Coon, J.T., Ernst, E., 2004. *Andrographis paniculata* in the treatment of upper
 813 respiratorytract infections: a systematic review of safety and efficacy. *Planta.*
 814 *Med.* 70, 293–298. <https://doi.org/10.1055/s-2004-818938>.
 815 Cordes, A.K., Heim, A., 2020. Rapid random-access detection of the novel SARS-
 816 coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access
 817 protocol for the Panther Fusion. *J. Clin. Virol.* 125, 104305.
 818 <https://doi.org/10.1016/j.jcv.2020.104305>.
 819 Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N., Decroly, E., 2020.
 820 The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-
 821 like cleavage site absent in CoV of the same clade. *Antivir. Res.* 176, 104742.
 822 <https://doi.org/10.1016/j.antiviral.2020.104742>.
 823 Cragg, G.M., Newman, D.J., Snader, K.M., 1997. Natural products in drug discovery
 824 and development. *J. Nat. Prod.* 60, 52–60. <https://doi.org/10.1021/np9604893>.

- De Clercq, E., 2007. Three decades of antiviral drugs. *Nat. Rev. Drug. Discov.* 6, 941–941. <https://doi.org/10.1038/nrd2485>.
- De Clercq, E., 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. *Int. J. Antimicrob. Agents.* 33, 307–320. <https://doi.org/10.1016/j.ijantimicag.2008.10.010>.
- De Haan, C.A., Rottier, P.J., 2005. Molecular interactions in the assembly of coronaviruses. *Adv. Virus. Res.* 64, 165–230. [https://doi.org/10.1016/S0065-3527\(05\)64006-7](https://doi.org/10.1016/S0065-3527(05)64006-7).
- Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Ying, Ning, L., Chen, L., Li, M., Liu, Yueping, Wang, G., 2020. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv*. <https://doi.org/10.1101/2020.02.18.20024364>.
- Dorigatti, I., Okell, L., Cori, A., Imai, N., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z., Cuomo-Dannenburg, G., FitzJohn, R., 2020. Report 4: Severity of 2019-novel coronavirus (nCoV). Imperial College. <https://doi.org/10.25561/77154>.
- Dubé, M., Le Coupanec, A., Wong, A.H., Rini, J.M., Desforges, M., Talbot, P.J., 2018. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. *J. Virol.* 92, 404–18. <https://doi.org/10.1128/JVI.00404-18>.
- Edwin, G.T., Korsik, M., Todd, M.H., 2019. The past, present and future of anti-malarial medicines. *Mala. J.* 18, 93. <https://doi.org/10.1186/s12936-019-2724-z>.
- Elfiky, A.A., 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life. Sci.* 248, 117477. <https://doi.org/10.1016/j.lfs.2020.117477>.
- Fabricant, D.S., Farnsworth, N.R., 2001. The value of plants used in traditional medicine for drug discovery. *Environ. Health. Perspect.* 109, 69–75. <https://doi.org/10.1289/ehp.01109s169>.
- Fehr, A.R., Perlman, S., 2015. Coronaviruses: an overview of their replication and pathogenesis. *Methods. Mol. Biol.* 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1.
- Fiore, C., Eisenhut, M., Krausse, R., Ragazzi, E., Pellati, D., Armanini, D., Bielenberg, J., 2008. Antiviral effects of Glycyrrhiza species. *Phytother. Res.* 22, 141–148. <https://doi.org/10.1002/ptr.2295>.
- Galani, V.J., Patel, B.G., Rana, D.G., 2010. *Sphaeranthus indicus* Linn.: A phytopharmacological review. *Int. J. Ayurveda. Res.* 1, 247–253. <https://doi.org/10.4103/0974-7788.76790>.
- Ganjhu, R.K., Mudgal, P.P., Maity, H., Dowarha, D., Devadiga, S., Nag, S., Arunkumar, G., 2015. Herbal plants and plant preparations as remedial approach for viral diseases. *Virusdisease.* 26, 225–236. <https://doi.org/10.1007/s13337-015-0276-6>.
- Gierer, S., Bertram, S., Kaup, F., Wrensch, F., Heurich, A., Krämer-Kühl, A., Welsch, K., Winkler, M., Meyer, B., Drosten, C., 2013. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. *J. Virol.* 87, 5502–5511. <https://doi.org/10.1128/JVI.00128-13>.
- Gilani, A.H., Khan, A., Raoof, M., Ghayur, M.N., Siddiqui, B.S., Vohra, W., Begum, S., 2008. Gastrointestinal, selective airways and urinary bladder relaxant effects of *Hyoscyamus niger* are mediated through dual blockade of muscarinic receptors and Ca²⁺ channels. *Fundam. Clin. Pharmacol.* 22, 87–99. <https://doi.org/10.1111/j.1472-8206.2007.00561.x>.

- Glass, W.G., Subbarao, K., Murphy, B., Murphy, P.M., 2004. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *J. Immunol.* 173, 4030–4039. <https://doi.org/10.4049/jimmunol.173.6.4030>.
- Gomathi, M., Padmapriya, S., Balachandar, V., 2020. Drug Studies on Rett Syndrome: From Bench to Bedside. *J. Autism. Dev. Disord.* 1–25. <https://doi.org/10.1007/s10803-020-04381-y>.
- Gorbalenya, A.E., 2020. Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group. *BioRxiv*. <https://doi.org/10.1101/2020.02.07.937862>.
- Gorbalenya, A.E., Baker, S.C., Baric, R.S., de Groot, R.J., Drosten, C., Gulyaeva, A.A., Haagmans, B.L., Lauber, C., Leontovich, A.M., Neuman, B.W., Penzar, D., Perlman, S., Poon, L.L.M., Samborskiy, D.V., Sidorov, I.A., Sola, I., Ziebuhr, J., 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* 5, 536–544. <https://doi.org/10.1038/s41564-020-0695-z>.
- Guarner, J., 2020. Three Emerging Coronaviruses in Two Decades The Story of SARS, MERS, and Now COVID-19. *Am. J. Clin. Path.* 153, 420–421. <https://doi.org/10.1093/ajcp/aqaa029>.
- Gurib-Fakim, A., 2006. Medicinal plants: traditions of yesterday and drugs of tomorrow. *Mol. Aspects. Med.* 27, 1–93. <https://doi.org/10.1016/j.mam.2005.07.008>.
- Haagmans, B.L., Kuiken, T., Martina, B.E., Fouchier, R.A., Rimmelzwaan, G.F., Van Amerongen, G., van Riel, D., De Jong, T., Itamura, S., Chan, K.-H., 2004. Pegylated interferon- α protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat. Med.* 10, 290–293. <https://doi.org/10.1038/nm1001>.
- Habibzadeh, P., Stoneman, E.K., 2020. The Novel Coronavirus: A Bird’s Eye View. *Int. J. Occup. Environ. Med.* 11, 65. <https://doi.org/10.15171/ijoem.2020.1921>.
- Harcourt, B.H., Jukneliene, D., Kanjanahaluethai, A., Bechill, J., Severson, K.M., Smith, C.M., Rota, P.A., Baker, S.C., 2004. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. *J. Virol.* 78, 13600–13612. <https://doi.org/10.1128/JVI.78.24.13600-13612.2004>.
- He, L., Qi, Y., Rong, X., Jiang, J., Yang, Q., Yamahara, J., Murray, M., Li, Y., 2011. The Ayurvedic medicine *Salacia oblonga* attenuates diabetic renal fibrosis in rats: suppression of angiotensin II/AT1 signaling. *Evid. Based. Complement. Alternat. Med.* 2011,12. <https://doi.org/10.1093/ecam/nep095>.
- Heymann, D.L., Shindo, N., 2020. COVID-19: what is next for public health?. *The Lancet.* 395, 542–545. [https://doi.org/10.1016/S0140-6736\(20\)30374-3](https://doi.org/10.1016/S0140-6736(20)30374-3).
- Hoffmann, M., Kleine-Weber, H., Krueger, N., Mueller, M.A., Drosten, C., Pöhlmann, S., 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. *BioRxiv*. <https://doi.org/10.1101/2020.01.31.929042>.
- Howard, M.W., Travanty, E.A., Jeffers, S.A., Smith, M., Wennier, S.T., Thackray, L.B., Holmes, K.V., 2008. Aromatic amino acids in the juxtamembrane domain of severe acute respiratory syndrome coronavirus spike glycoprotein are important for receptor-dependent virus entry and cell-cell fusion. *J. Virol.* 82, 2883–2894. <https://doi.org/10.1128/JVI.01805-07>.

925 Hsieh, L. E., Lin, C.N., Su, B.L., Jan, T.R., Chen, C.M., Wang, C.H., Lin, D.S., Lin,
926 C.T., Chueh, L.L., 2010. Synergistic antiviral effect of *Galanthus nivalis*
927 agglutinin and nelfinavir against feline coronavirus. *Antiviral. Res.* 88, 25–30.
928 <https://doi.org/10.1016/j.antiviral.2010.06.010>.

929 Hu, F., Jiang, J., Yin, P., 2020. Prediction of potential commercially inhibitors against
930 SARS-CoV-2 by multi-task deep model. *arXiv:2003.00728*.

931 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,
932 X., 2020. Clinical features of patients infected with 2019 novel coronavirus in
933 Wuhan, China. *The Lancet.* 395, 497–506. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)30183-5)
934 [6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).

935 Hussain, F., Jahan, N., Rahman, K., Sultana, B., Jamil, S., 2018. Identification of
936 Hypotensive Biofunctional Compounds of *Coriandrum sativum* and
937 Evaluation of Their Angiotensin-Converting Enzyme (ACE) Inhibition
938 Potential. *Oxid. Med. Cell. Longev.* 3, 1–11.
939 <https://doi.org/10.1155/2018/4643736>.

940 Indian Council of Medical Research (ICMR), 2020. [https://icmr.nic.in/sites](https://icmr.nic.in/sites/default/files/whats_new/ICMR_website_update_25March_8PM_IST.pdf)
941 [/default/files/whats_new/ICMR_website_update_25March_8PM_IST.pdf](https://icmr.nic.in/sites/default/files/whats_new/ICMR_website_update_25March_8PM_IST.pdf).

942 Imbert, I., Guillemot, J., Bourhis, J., Bussetta, C., Coutard, B., Egloff, M., Ferron, F.,
943 Gorbalenya, A.E., Canard, B., 2006. A second, non-canonical RNA-dependent
944 RNA polymerase in SARS Coronavirus. *EMBO. J.* 25, 4933–4942.
945 <https://doi.org/10.1038/sj.emboj.7601368>.

946 Janice Oh, H.L., Ken-En Gan, S., Bertoletti, A., Tan, Y.J., 2012. Understanding the T
947 cell immune response in SARS coronavirus infection. *Emerg. Microbes.*
948 *Infect.* 1, 1–6. <https://doi.org/10.1038/emi.2012.26>.

949 Jiang, S., Shi, Z., Shu, Y., Song, J., Gao, G.F., Tan, W., Guo, D., 2020. A distinct
950 name is needed for the new coronavirus. *The Lancet.* 395, 949
951 [https://doi.org/10.1016/S0140-6736\(20\)30419-0](https://doi.org/10.1016/S0140-6736(20)30419-0).

952 Jiang, X., Kanda, T., Nakamoto, S., Saito, K., Nakamura, M., Wu, S., Haga, Y.,
953 Sasaki, R., Sakamoto, N., Shirasawa, H., 2015. The JAK2 inhibitor AZD1480
954 inhibits hepatitis A virus replication in Huh7 cells. *Biochem. Biophys. Res.*
955 *Commun.* 458, 908–912. <https://doi.org/10.1016/j.bbrc.2015.02.058>.

956 Jin, Y.H., Cai, L., Cheng, Z.S., Cheng, H., Deng, T., Fan, Y.P., Fang, C., Huang, D.,
957 Huang, L.Q., Huang, Q., 2020. A rapid advice guideline for the diagnosis and
958 treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia
959 (standard version). *Military. Med. Res.* 7, 4. [https://doi.org/10.1186/s40779-](https://doi.org/10.1186/s40779-020-0233-6)
960 [020-0233-6](https://doi.org/10.1186/s40779-020-0233-6).

961 Kannan, S., Ali, P.S.S., Sheeza, A., Hemalatha, K., 2020. COVID-19 (Novel
962 Coronavirus 2019)—recent trends. *Eur. Rev. Med. Pharmacol. Sci.* 24, 2006–
963 2011. https://doi.org/10.26355/eurrev_202002_20378.

964 Karakus, U., Pohl, M.O., Stertz, S., 2020. Breaking the Convention: Sialoglycan
965 Variants, Coreceptors, and Alternative Receptors for Influenza A Virus Entry.
966 *J. Virol.* 94. <https://doi.org/10.1128/JVI.01357-19>.

967 Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., Matsuyama, S., 2012.
968 Simultaneous treatment of human bronchial epithelial cells with serine and
969 cysteine protease inhibitors prevents severe acute respiratory syndrome
970 coronavirus entry. *J. Virol.* 86, 6537–6545. [https://doi.org/10.1128/JVI.00094-](https://doi.org/10.1128/JVI.00094-12)
971 [12](https://doi.org/10.1128/JVI.00094-12).

972 Keyaerts, E., Li, S., Vijgen, L., Rysman, E., Verbeeck, J., Van Ranst, M., Maes, P.,
973 2009. Antiviral activity of chloroquine against human coronavirus OC43

974 infection in newborn mice. *Antimicrob. Agents. Chemother.* 53, 3416–3421.
975 <https://doi.org/10.1128/AAC.01509-08>.

976 Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M., 2004. In vitro inhibition
977 of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem.*
978 *Biophys. Res. Commun.* 323, 264–268.
979 <https://doi.org/10.1016/j.bbrc.2004.08.085>.

980 Keyaerts, E., Vijgen, L., Pannecouque, C., Van Damme, E., Peumans, W., Egberink,
981 H., Balzarini, J., Van Ranst, M., 2007. Plant lectins are potent inhibitors of
982 coronaviruses by interfering with two targets in the viral replication cycle.
983 *Antivir. Res.* 75, 179–187. <https://doi.org/10.1016/j.antiviral.2007.03.003>.

984 Khan, M.Y., Kumar, V., 2019. Mechanism & inhibition kinetics of bioassay-guided
985 fractions of Indian medicinal plants and foods as ACE inhibitors. *J. Tradit.*
986 *Complement. Med.* 9, 73–84. <https://doi.org/10.1016/j.jtcme.2018.02.001>.

987 Kilianski, A., Mielech, A.M., Deng, X., Baker, S.C., 2013. Assessing activity and
988 inhibition of Middle East respiratory syndrome coronavirus papain-like and
989 3C-like proteases using luciferase-based biosensors. *J. Virol.* 87, 11955–
990 11962. <http://doi.org/10.1128/JVI.02105-13>.

991 Killerby, M.E., Biggs, H.M., Haynes, A., Dahl, R.M., Mustaquim, D., Gerber, S.I.,
992 Watson, J.T., 2018. Human coronavirus circulation in the United States 2014–
993 2017. *J. Clin. Virol.* 101, 52–56. <https://doi.org/10.1016/j.jcv.2018.01.019>.

994 Konrad, R., Eberle, U., Dangel, A., Treis, B., Berger, A., Bengs, K., Fingerle, V.,
995 Liebl, B., Ackermann, N., Sing, A., 2020. Rapid establishment of laboratory
996 diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany,
997 February 2020. *Euro. Surveill.* 25, 2000173. <https://doi.org/10.2807/1560-7917.ES.2020.25.9.2000173>.

998
999 Kruse, R.L., 2020. Therapeutic strategies in an outbreak scenario to treat the novel
1000 coronavirus originating in Wuhan, China. *F1000Res.* 9,72.
1001 <https://doi.org/10.12688/f1000research.22211.2>

1002 Lei, P., Fan, B., Mao, J., Wang, P., 2020. Comprehensive analysis for diagnosis of
1003 novel coronavirus disease (COVID-19) infection. *J.*
1004 *Infect.* <https://doi.org/10.1016/j.jinf.2020.03.016>

1005 Lewinsohn, D.M., Bowden, R.A., Mattson, D., Crawford, S.W., 1996. Phase I study
1006 of intravenous ribavirin treatment of respiratory syncytial virus pneumonia
1007 after marrow transplantation. *Antimicrob. Agents. Chemother.* 40, 2555–2557.

1008 Leyva-Grado, V.H., Behzadi, M.A., 2019. Overview of current therapeutics and novel
1009 candidates against influenza, respiratory syncytial virus and Middle East
1010 respiratory syndrome coronavirus infections. *Fronti. Microbiol.* 10, 1327.
1011 <https://doi.org/10.3389/fmicb.2019.01327>

1012 Li, G., Clercq, E., 2020. Therapeutic options for the 2019 novel coronavirus (2019-
1013 nCoV). *Nat. Rev. Drug. Discov.* 19, 1449–150.
1014 <https://doi.org/10.1038/d41573-020-00016-0>

1015 Li, Y., Bai, W., Hashikawa, T., 2020. The neuroinvasive potential of SARS-CoV2
1016 may be at least partially responsible for the respiratory failure of COVID-19
1017 patients. *J. Med. Virol.* <https://doi.org/10.1002/jmv.25728>

1018 Li, Z., He, W., Lan, Y., Zhao, K., Lv, X., Lu, H., Ding, N., Zhang, J., Shi, J., Shan,
1019 C., 2016. The evidence of porcine hemagglutinating encephalomyelitis virus
1020 induced nonsuppurative encephalitis as the cause of death in piglets. *Peer. J.* 4,
1021 2443. <https://doi.org/10.7717/peerj.2443>

1022 Lin, S., Shen, R., He, J., Li, X., Guo, X., 2020. Molecular Modeling Evaluation of the
1023 Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute

1024 Respiratory Syndrome Coronavirus 2 Proteases. BioRxiv.
1025 <https://doi.org/10.1101/2020.01.31.929695>

1026 Liou, C.J., Cheng, C.Y., Yeh, K.W., Wu, Y.H., Huang, W.C., 2018. Protective effects
1027 of casticin from vitex trifolia alleviate eosinophilic airway inflammation and
1028 oxidative stress in a murine asthma model. *Front. Pharma col.* 9, 635.
1029 <https://doi.org/10.3389/fphar.2018.00635>

1030 Lippi, G., Simundic, A.M., Plebani, M., 2020. Potential preanalytical and analytical
1031 vulnerabilities in the laboratory diagnosis of coronavirus disease 2019
1032 (COVID-19). *Clin. Chem. Lab. Med.* <http://doi.org/10.1515/cclm-2020-0285>

1033 Liu, D.X., Fung, T.S., Chong, K.K.-L., Shukla, A., Hilgenfeld, R., 2014. Accessory
1034 proteins of SARS-CoV and other coronaviruses. *Antiviral. Res.* 109, 97–109.
1035 <https://doi.org/10.1016/j.antiviral.2014.06.013>

1036 Liu, Y.T., Chen, H.W., Lii, C.K., Jhuang, J.H., Huang, C.S., Li, M.L., Yao, H.T.,
1037 2020. A Diterpenoid, 14-Deoxy-11, 12-Didehydroandrographolide, in
1038 *Andrographis paniculata* Reduces Steatohepatitis and Liver Injury in Mice Fed
1039 a High-Fat and High-Cholesterol Diet. *Nutrients.* 12, 523.
1040 <https://doi.org/10.3390/nu12020523>

1041 Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., Liu, L.,
1042 2020. Composition and divergence of coronavirus spike proteins and host
1043 ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med.*
1044 *Virol.* <https://doi.org/10.1002/jmv.25726>.

1045 Li-Weber, M., 2009. New therapeutic aspects of flavones: the anticancer properties of
1046 *Scutellaria* and its main active constituents Wogonin, Baicalein and Baicalin.
1047 *Cancer. Treat. Rev.* 35, 57–68. <https://doi.org/10.1016/j.ctrv.2008.09.005>

1048 Loeffelholz, M.J., Tang, Y.W., 2020. Laboratory Diagnosis of Emerging Human
1049 Coronavirus Infections- The State of the Art. *Emerg. Microbes. Infect.* 1-26.
1050 <https://doi.org/10.1080/22221751.2020.1745095>

1051 Lu, H., 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV).
1052 *Biosci. Trends.* <https://doi.org/10.5582/bst.2020.01020>

1053 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B.,
1054 Zhu, N., 2020. Genomic characterisation and epidemiology of 2019 novel
1055 coronavirus: implications for virus origins and receptor binding. *The Lancet*
1056 395, 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)

1057 Mahy, B.W., Siddell, S., Wege, H., Ter Meulen, V., 1983. RNA-dependent RNA
1058 polymerase activity in murine coronavirus-infected cells. *J. Gen. Virol.* 64,
1059 103–111.

1060 Maity, N., Nema, N.K., Sarkar, B.K., Mukherjee, P.K., 2012. Standardized *Clitoria*
1061 *ternatea* leaf extract as hyaluronidase, elastase and matrix-metalloproteinase-1
1062 inhibitor. *Indian. J. pharmacol.* 44, 584. <https://doi.org/10.4103/0253-7613.100381>

1064 Maloir, Q., Ghysen, K., Louis, R., Guiot, J., 2018. Acute respiratory distress revealing
1065 antisynthetase syndrome. *Rev. Med. Liege.* 73, 370–375.

1066 Manni, M.L., Robinson, K.M., Alcorn, J.F., 2014. A tale of two cytokines: IL-17 and
1067 IL-22 in asthma and infection. *Expert. Rev. Respir. Med.* 8, 25–42.
1068 <https://doi.org/10.1586/17476348.2014.854167>.

1069 March, K., Bogatcheva, N., 2018. Use of asc and asc-cm to treat ards, sars, and mers.
1070 <http://www.freepatentsonline.com/10143709.html>

1071 Markland, W., McQuaid, T., Jain, J., Kwong, A., 2000. Broad-spectrum antiviral
1072 activity of the IMP dehydrogenase inhibitor VX-497: a comparison with
1073 ribavirin and demonstration of antiviral additivity with alpha interferon.

1074 Antimicrob. Agents. Chemother. 44, 859–866.
1075 <https://doi.org/10.1128/aac.44.4.859-866.2000>
1076 Matsuda, K., Park, C., Sunden, Y., Kimura, T., Ochiai, K., Kida, H., Umemura, T.,
1077 2004. The vagus nerve is one route of transneural invasion for intranasally
1078 inoculated influenza a virus in mice. Vet. pathol. 41, 101–107.
1079 <https://doi.org/10.1354/vp.41-2-101>.
1080 Matthew A., 2020. Lost smell and taste hint COVID-19 can target the Nervous
1081 system. The Scientist. Published on 24th March, 2020.
1082 McIntosh, K., Kurachek, S.C., Cairns, L.M., Burns, J.C., Goodspeed, B., 1984.
1083 Treatment of respiratory viral infection in an immunodeficient infant with
1084 ribavirin aerosol. Am. J. Dis. Child. 138, 305–308.
1085 Mengeling, W., WL, M., AD, B., AE, R., 1972. Characteristics of a coronavirus
1086 (strain 67N) of pigs. Am. J. Vet. Res. 33, 297–308.
1087 Mishra, S., Aeri, V., Gaur, P.K., Jachak, S.M., 2014. Phytochemical, therapeutic, and
1088 ethnopharmacological overview for a traditionally important herb:
1089 Boerhaviadiffusa Linn. BioMed. Res. Int. 2014, 808302.
1090 <https://doi.org/10.1155/2014/808302>
1091 Moghadamtousi, S.Z., Nikzad, S., Kadir, H.A., Abubakar, S., Zandi, K., 2015.
1092 Potential antiviral agents from marine fungi: an overview. Mar. Drugs. 13,
1093 4520–4538. <https://doi.org/10.3390/md13074520>
1094 Mulangu, S., Dodd, L.E., Davey Jr, R.T., Tshiani Mbaya, O., Proschan, M., Mukadi,
1095 D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A.,
1096 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N.
1097 Engl. J. Med. 381, 2293–2303. <https://doi.org/10.1056/NEJMoa1910993>
1098 Nair, R., 2012. HIV-1 reverse transcriptase inhibition by Vitex negundo L. leaf
1099 extract and quantification of flavonoids in relation to anti-HIV activity. J. Cell.
1100 Mol. Biol. 10, 53–59.
1101 Nieto-Torres, J.L., Verdía-Báguena, C., Jimenez-Guardeño, J.M., Regla-Nava, J.A.,
1102 Castaño-Rodríguez, C., Fernandez-Delgado, R., Torres, J., Aguilera, V.M.,
1103 Enjuanes, L., 2015. Severe acute respiratory syndrome coronavirus E protein
1104 transports calcium ions and activates the NLRP3 inflammasome. Virology.
1105 485, 330–339. <https://doi.org/10.1016/j.virol.2015.08.010>
1106 Nourazarian, A., 2015. Effect of Root Extracts of Medicinal Herb Glycyrrhiza glabra
1107 on HSP90 Gene Expression and Apoptosis in the HT-29 Colon Cancer Cell
1108 Line. Asian. Pac. J. Cancer. Prev.2011,1-16.
1109 <https://doi.org/10.7314/APJCP.2015.16.18.8563>
1110 Olivieri, F., Prasad, V., Valbonesi, P., Srivastava, S., Ghosal-Chowdhury, P.,
1111 Barbieri, L., Bolognesi, A., Stirpe, F., 1996. A systemic antiviral resistance-
1112 inducing protein isolated from Clerodendrum inerme Gaertn. is a
1113 polynucleotide: adenosine glycosidase (ribosome-inactivating protein). FEBS
1114 letters. 396, 132–134.
1115 Otake, T., Mori, H., Morimoto, M., Ueba, N., Sutardjo, S., Kusumoto, I.T., Hattori,
1116 M., Namba, T., 1995. Screening of Indonesian plant extracts for anti-human
1117 immunodeficiency virus—type 1 (HIV-1) activity. Phytother. Res. 9, 6–10.
1118 Pan, P.P., Zhang, Q.T., Le, F. Zheng, Y.M. Jin F. 2013. Angiotensin-Converting
1119 Enzymes Play a Dominant Role in Fertility. Int. J. Mol. Sci. 14 (10): 21071-
1120 86. <https://doi.org/10.3390/ijms141021071>
1121 Pandey, A., Bigoniya, P., Raj, V., Patel, K. K. (2011). Pharmacological screening of
1122 Coriandrum sativum Linn. for hepatoprotective activity. J. Pharm. Bioallied.
1123 Sci. 3(3), 435. <https://doi.org/10.4103/0975-7406.84462>

1124 Parasuraman, S., Thing, G.S., Dhanaraj, S.A., 2014. Polyherbal formulation: Concept
 1125 of ayurveda. *Pharmacogn. Rev.* 8, 73. [https://doi.org/ 10.4103/0973-](https://doi.org/10.4103/0973-7847.134229)
 1126 7847.134229

1127 Peiris, J., Guan, Y., Yuen, K., 2004. Severe acute respiratory syndrome. *Nat. Med.* 10,
 1128 S88–S97. <https://doi.org/10.1038/nm1143>

1129 Peters, H.L., Jochmans, D., de Wilde, A.H., Posthuma, C.C., Snijder, E.J., Neyts, J.,
 1130 Seley-Radtke, K.L., 2015. Design, synthesis and evaluation of a series of
 1131 acyclic fleximer nucleoside analogues with anti-coronavirus activity. *Bioorg.*
 1132 *Med. Chem. Lett.* 25, 2923–2926. <https://doi.org/10.1016/j.bmcl.2015.05.039>

1133 Phan, T., 2020. Novel coronavirus: From discovery to clinical diagnostics. *Infect.*
 1134 *Genet. Evo.* 79, 104211. <https://doi.org/10.1016/j.meegid.2020.104211>

1135 Prathapan, A., Vineetha, V., Abhilash, P., Raghu, K., 2013. Boerhaaviadiffusa L.
 1136 attenuates angiotensin II-induced hypertrophy in H9c2 cardiac myoblast cells
 1137 via modulating oxidative stress and down-regulating NF- κ B and transforming
 1138 growth factor β 1. *Br. J. Nutr.* 110, 1201–1210.
 1139 <https://doi.org/10.1017/S0007114513000561>

1140 Pundarikakshudu, K., Kanaki, N.S., 2019. Analysis and Regulation of Traditional
 1141 Indian Medicines (TIM). *J. AOAC. Int.* 102, 977–978.
 1142 <https://doi.org/10.5740/jaoacint.18-0376>

1143 Que, T., Wong, V., Yuen, K., 2003. Treatment of severe acute respiratory syndrome
 1144 with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
 1145 *Hong Kong Med J.* 9, 399–406.

1146 Ravishankar, B., Shukla, V., 2007. Indian systems of medicine: a brief profile. *Afr. J.*
 1147 *Trad. Complement. Altern. Med.* 4, 319–337.
 1148 <https://doi.org/10.4314/ajtcam.v4i3.31226>

1149 Razonable, R.R., 2011. Antiviral drugs for viruses other than human
 1150 immunodeficiency virus. *Mayo. Clin. Proc.* 86,1009–1026.
 1151 <https://doi.org/10.4065/mcp.2011.0309>

1152 Rege, A., Chowdhary, A.S., 2014. Evaluation of Ocimum sanctum and Tinospora
 1153 cordifolia as probable HIV protease inhibitors. *Int. J. of Pharm. Sci. Rev. Res.*
 1154 25, 315–318.

1155 Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Stebbing,
 1156 J., 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory
 1157 disease. *The Lancet.* 395, 30-31. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)30304-4)
 1158 6736(20)30304-4

1159 Rossignol, J.-F., 2016. Nitazoxanide, a new drug candidate for the treatment of
 1160 Middle East respiratory syndrome coronavirus. *J. Infect. Public. Health.* 9,
 1161 227–230. <https://doi.org/10.1016/j.jiph.2016.04.001>

1162 Rudra, S., Kalra, A., Kumar, A., Joe, W., 2017. Utilization of alternative systems of
 1163 medicine as health care services in India: evidence on AYUSH care from NSS
 1164 2014. *PloS one* 12, e0176916. <https://doi.org/10.1371/journal.pone.0176916>

1165 Schoeman, D., Fielding, B.C., 2019. Coronavirus envelope protein: current
 1166 knowledge. *Virology. J.* 16, 69. <https://doi.org/10.1186/s12985-019-1182-0>

1167 Scior, T., Bender, A., Tresadern, G., Medina-Franco, J.L., Martínez-Mayorga, K.,
 1168 Langer, T., Cuanalo-Contreras, K., Agrafiotis, D.K., 2012. Recognizing
 1169 pitfalls in virtual screening: a critical review. *J. Chem. Inf. Model.* 52, 867–
 1170 881. <https://doi.org/10.1021/ci200528d>

1171 Shanti, B.M. 2016. Perspective of Potential Plants for Medicine from Rajasthan,
 1172 India, *Int. J. Pharm. Res.* 7(1);1-6.

1173 Shi, C.-S., Nabar, N.R., Huang, N.-N., Kehrl, J.H., 2019. SARS-Coronavirus Open
1174 Reading Frame-8b triggers intracellular stress pathways and activates NLRP3
1175 inflammasomes. *Cell. Death. Discov.* 5, 1–12. [https://doi.org/10.1038/s41420-](https://doi.org/10.1038/s41420-019-0181-7)
1176 019-0181-7

1177 Simmons, G., Zmora, P., Gierer, S., Heurich, A., Pöhlmann, S., 2013. Proteolytic
1178 activation of the SARS-coronavirus spike protein: cutting enzymes at the
1179 cutting edge of antiviral research. *Antiviral. Res.* 100, 605–614.
1180 <https://doi.org/10.1016/j.antiviral.2013.09.028>

1181 Siu, K.L., Yuen, K.S., Castaño-Rodriguez, C., Ye, Z.W., Yeung, M.L., Fung, S.Y.,
1182 Yuan, S., Chan, C.P., Yuen, K.Y., Enjuanes, L., 2019. Severe acute
1183 respiratory syndrome coronavirus ORF3a protein activates the NLRP3
1184 inflammasome by promoting TRAF3-dependent ubiquitination of ASC.
1185 *FASEB. J.* 33, 8865–8877. <https://doi.org/10.1096/fj.201802418R>

1186 Siu, Y., Teoh, K., Lo, J., Chan, C., Kien, F., Escriou, N., Tsao, S., Nicholls, J.,
1187 Altmeyer, R., Peiris, J., 2008. The M, E, and N structural proteins of the
1188 severe acute respiratory syndrome coronavirus are required for efficient
1189 assembly, trafficking, and release of virus-like particles. *J. Virol.* 82, 11318–
1190 11330. <https://doi.org/10.1128/JVI.01052-08>

1191 Shi, F., Yu, Q., Huang, W., Tan, C., 2020. 2019 Novel Coronavirus (COVID-19)
1192 Pneumonia with Hemoptysis as the Initial Symptom: CT and Clinical
1193 Features. *Korean. J. Radiol.* <https://doi.org/10.1148/radiol.2020200490>

1194 Shirato, K., Yano, T., Senba, S., Akachi, S., Kobayashi, T., Nishinaka, T., Notomi, T.,
1195 Matsuyama, S., 2014. Detection of Middle East respiratory syndrome
1196 coronavirus using reverse transcription loop-mediated isothermal
1197 amplification (RT-LAMP). *Virol. J.* 11, 139. [https://doi.org/10.1186/1743-](https://doi.org/10.1186/1743-422X-11-139)
1198 422X-11-139

1199 Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., Qin,
1200 C., 2019. From SARS to MERS, thrusting coronaviruses into the spotlight.
1201 *Viruses.* 11, 59. <https://doi.org/10.3390/v11010059>

1202 Srivastava, R.A.K., Mistry, S., Sharma, S., 2015. A novel anti-inflammatory natural
1203 product from *Sphaeranthus indicus* inhibits expression of VCAM1 and
1204 ICAM1, and slows atherosclerosis progression independent of lipid changes.
1205 *Nutr. Metab.* 12, 20. <https://doi.org/10.1186/s12986-015-0018-1>

1206 Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., Richardson,
1207 P., 2020. COVID-19: combining antiviral and anti-inflammatory treatments.
1208 *Lancet. Infect. Dis.* [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8)

1209 Sumithira, P., Mangala, S., Sophie, A., Latha, C., 2012. Antiviral and antioxidant
1210 activities of two medicinal plants. *Int J Curr Sci* 256, 261.

1211 Tabuti, J.R., Lye, K.A., Dhillon, S., 2003. Traditional herbal drugs of Bulamogi,
1212 Uganda: plants, use and administration. *J. Ethnopharmacol.* 88, 19–44.
1213 [https://doi.org/10.1016/S0378-8741\(03\)00161-2](https://doi.org/10.1016/S0378-8741(03)00161-2)

1214 Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., Du, L., 2020.
1215 Characterization of the receptor-binding domain (RBD) of 2019 novel
1216 coronavirus: implication for development of RBD protein as a viral
1217 attachment inhibitor and vaccine. *Cell. Mol. Immunol.* 1–8.
1218 <https://doi.org/10.1038/s41423-020-0400-4>

1219 Talbot, P.J., Ékandé, S., Cashman, N.R., Mounir, S., Stewart, J.N., 1994.
1220 Neurotropism of human coronavirus 229E. *Coronaviruses.* 339–346.

1221 Tan, E.L., Ooi, E.E., Lin, C.Y., Tan, H.C., Ling, A.E., Lim, B., Stanton, L.W., 2004.
1222 Inhibition of SARS coronavirus infection in vitro with clinically approved

1223 antiviral drugs. Emerg. Infect. Dis. 10, 581.
1224 <https://doi.org/10.3201/eid1004.030458>
1225 Thayil Seema, M., Thyagarajan, S., 2016. Methanol and aqueous extracts of *Ocimum*
1226 *kilimandscharicum* (Karpuratulasi) inhibits HIV-1 reverse transcriptase in
1227 vitro. *Int. J. Pharmacogn. Phytochem. Res* 8, 1099–1103.
1228 Tiwari, B.K., Khosa, R. L., 2009. Hepatoprotective and antioxidant effect of
1229 *Sphaeranthus indicus* against acetaminophen-induced hepatotoxicity in rats. *J.*
1230 *Pharm. Sci. Res.* 1, 26-30.
1231 Tsai, Y.C., Lee, C.L., Yen, H.R., Chang, Y.S., Lin, Y.P., Huang, S.H., Lin, C.W.,
1232 2020. Antiviral Action of Tryptanthrin Isolated from *Strobilanthes cusia* Leaf
1233 against Human Coronavirus NL63. *Biomolecules* 10, 366.
1234 <https://doi.org/10.3390/biom10030366>
1235 Vimalanathan, S., Ignacimuthu, S., Hudson, J., 2009. Medicinal plants of Tamil Nadu
1236 (Southern India) are a rich source of antiviral activities. *Pharm. Biol.* 47, 422–
1237 429. <https://doi.org/10.1080/13880200902800196>
1238 Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek,
1239 T.G., Seidah, N.G., Nichol, S.T., 2005. Chloroquine is a potent inhibitor of
1240 SARS coronavirus infection and spread. *Virol. J.* 2, 69.
1241 <https://doi.org/10.1186/1743-422X-2-69>
1242 Walker, L.M., Burton, D.R., 2018. Passive immunotherapy of viral infections: 'super-
1243 antibodies' enter the fray. *Nat. Rev. Immunol.* 18, 297.
1244 <https://doi.org/10.1038/nri.2017.148>
1245 Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020.
1246 Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
1247 Cell S0092-8674(20)30262-2. <https://doi.org/10.1016/j.cell.2020.02.058>
1248 Wan, Y., Shang, J., Graham, R., Baric, R.S., Li, F., 2020. Receptor recognition by
1249 novel coronavirus from Wuhan: An analysis based on decade-long structural
1250 studies of SARS. *J. Virol.* <https://doi.org/10.1128/JVI.00127-20>
1251 Wang, L., Wang, Y., Ye, D., Liu, Q., 2020. A review of the 2019 Novel Coronavirus
1252 (COVID-19) based on current evidence. *Int. J. Antimicrob. Agents.* 105948.
1253 <https://doi.org/10.1016/j.ijantimicag.2020.105948>
1254 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z.,
1255 Xiong, Y., 2020. Clinical characteristics of 138 hospitalized patients with
1256 2019 novel coronavirus–infected pneumonia in Wuhan, China. *Jama.* 323,
1257 1061-1069. <https://doi.org/10.1001/jama.2020.1585>
1258 Wang, J., 2020. Fast Identification of Possible Drug Treatment of Coronavirus
1259 Disease-19 (COVID-19) Through Computational Drug Repurposing Study.
1260 ChemRxiv. <https://doi.org/10.26434/chemrxiv.11875446.v1>
1261 Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W.,
1262 Xiao, G., 2020. Remdesivir and chloroquine effectively inhibit the recently
1263 emerged novel coronavirus (2019-nCoV) in vitro. *Cell. Res.* 1–3.
1264 <https://doi.org/10.1038/s41422-020-0282-0>
1265 Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., Siegel,
1266 D., Perron, M., Bannister, R., Hui, H.C., 2016. Therapeutic efficacy of the
1267 small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature.* 531,
1268 381–385. <https://doi.org/10.1038/nature17180>
1269 World Health Organization (WHO), 2020a. Laboratory testing of 2019 novel
1270 coronavirus (2019-nCoV) in suspected human cases. [https://apps.who.int](https://apps.who.int/iris/handle/10665/330676)
1271 /iris/handle/10665/330676

World Health Organization (WHO), 2020b. Novel Coronavirus (2019-nCoV) situation report. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

World Health Organization (WHO), 2020c. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. <https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/>

World Health Organization (WHO), 2020d. Surveillance case definitions for human infection with novel coronavirus (nCoV). <https://apps.who.int/iris/handle/10665/330376>.

Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., 2020. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell. Host. Microbe.* 27, 325–328. <https://doi.org/10.1016/j.chom.2020.02.001>

Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta. Pharm. Sin. B.* <https://doi.org/10.1016/j.apsb.2020.02.008>

Wu, Z., McGoogan, J.M., 2020. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* <https://doi.org/10.1001/jama.2020.2648>

Xu, J., Zhao, S., Teng, T., Abdalla, A.E., Zhu, W., Xie, L., Wang, Y., Guo, X., 2020. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. *Viruses* 12, 244. <https://doi.org/10.3390/v12020244>

Xu, X., Yu, C., Qu, J., Zhang, L., Jiang, S., Huang, D., Chen, B., Zhang, Z., Guan, W., Ling, Z., 2020. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur. J. Nucl. Med. and Mol. Imaging* 1–6. <https://doi.org/10.1007/s00259-020-04735-9>

Xu, Y., 2020. Unveiling the Origin and Transmission of 2019-nCoV. *Trends. Microbiol.* 28, 239–240. <https://doi.org/10.1016/j.tim.2020.02.001>

Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.-F., Wei, Y., Jin, N., Jiang, C., 2013. Antimalarial drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. *Cell. Res.* 23, 300–302. <https://doi.org/10.1038/cr.2012.165>

Yang, Y., Xiong, Z., Zhang, S., Yan, Y., Nguyen, J., Ng, B., Lu, H., Brendese, J., Yang, F., Wang, H., 2005. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. *Biochem. J.* 392, 135–143. <https://doi.org/10.1042/BJ20050698>

Yarnell, E., 2018. Herbs for Viral Respiratory Infections. *Altern. Complement. Ther.* 24, 35–43. <https://doi.org/10.1089/act.2017.29150.eya>

Yin, Y., Wunderink, R.G., 2018. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology* 23, 130–137. <https://doi.org/10.1111/resp.13196>

Youngchang, K., Robert, J., Natalia, M., Michael, E., Adam, G., Karolina, M., Andrzej, J., 2020. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. *bioRxiv.* 968388. <https://doi.org/10.1101/2020.03.02.968388>

Yu, Y.-B., 2004. The Extracts of *Solanum nigrum* L. for inhibitory effects on HIV-1 and its essential enzymes. *Korean. J. Orient. Med.* 10, 119–126.

- Yuan, H., Ma, Q., Ye, L., Piao, G., 2016. The traditional medicine and modern medicine from natural products. *Molecules* 21, 559. <https://doi.org/10.3390/molecules21050559>
- Zaki, A.M., Van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N. Engl. J. Med.* 367, 1814–1820. <https://doi.org/10.1056/NEJMoa1211721>
- Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., Hilgenfeld, R., 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science*. eabb3405. <https://doi.org/10.1126/science.abb3405>
- Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W., 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV. *BioRxiv*. <https://doi.org/10.1101/2020.01.26.919985>
- Zheng, M., Song, L., 2020. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cell. Mol. Immunol.* 17,1-3. <https://doi.org/10.1038/s41423-020-0385-z>
- Zheng, Y., Ma, Y., Zhang, J., Xie, X., 2020. COVID-19 and the cardiovascular system. *Nat. Rev. Cardiol.* <https://doi.org/10.1038/s41569-020-0360-5>
- Zhou, X., Huang, F., Xu, L., Lin, Z., de Vrij, F., Ayo-Martin, A.C., van der Kroeg, M., Zhao, M., Yin, Y., Wang, W., 2017. Hepatitis E virus infects neurons and brains. *J. Infect. Dis.* 215, 1197–1206. <https://doi.org/10.1093/infdis/jix079>
- Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., Yuen, K.Y., 2016. Coronaviruses—drug discovery and therapeutic options. *Nat. Rev. Drug. Discov.* 15, 327. <https://doi.org/10.1038/nrd.2015.37>
- Zumla, A., Hui, D.S., Azhar, E.I., Memish, Z.A., Maeurer, M., 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *The Lancet* 395, 35-36. [https://doi.org/10.1016/S0140-6736\(20\)30305-6](https://doi.org/10.1016/S0140-6736(20)30305-6)

Table 1: Symptomatic comparison of COVID -19, SARS, MERS and Common Flu

Diseases	Symptoms	Onset of Disease	Incubation Period	Recovery	Transmission of Disease	Complications if any	Treatments if available
Novel Coronavirus (COVID-19)	Fever Cough Shortness of Breath Fatigue	Sudden	2-14 days after exposure	2-8 Weeks	Human to Human	Acute pneumonia, septic shock, respiratory failure in adverse condition.	No vaccines available, only symptoms can be treated.
Severe Acute Respiratory Syndrome (SARS)	Fever Dry Cough Headache Difficulty in breathing Muscle aches Loss of appetite Diarrhoea	Sudden	2-7 days after exposure	5- 6 Weeks	Human to Human	Heart, Liver and Respiratory failure in adverse condition.	Breathing ventilator to deliver oxygen. Pneumonia treating antibiotics Antiviral medicines Steroids to reduce lung swelling
Middle East Respiratory Syndrome (MERS)	Fever Chills Diarrhoea Nausea Vomiting Congestion Sneezing Sore throat	Sudden	5-6 days after exposure	6-7 Weeks	Human to Human	Acute pneumonia Kidney failure in adverse condition.	Treatment only for symptoms such as Fluids replacement Oxygen therapy.
Common Flu	Runny or Stuffy nose Sneezing Sore throat Mild Headache Low grade fever	Gradual	2-3 days after exposure	7-10 days	Human to Human	Extremely rare or None	Symptoms can be treated by medication.

Table 1 represents the parallel investigation of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Novel Coronavirus (COVID-19) and Common Flu with their Symptoms, Onset of Disease, Incubation Period, Recovery, Transmission of Disease, Complications and available treatments.

Table 2: The Detailed Report of Commercially Available Drugs in Treatment of COVID – 19

S.No.	Name of Drug	Illnesses treated	References
1.	α -interferon	Spectrum of respiratory infections, RSV and SARS	(Cinatl et al., 2003; Guerrero et al., 2013; Markland et al., 2000)
2.	Ritonavir and lopinavir	SARS, MERS	(Chu et al., 2004)
3.	Ribavirin	RSV and RSV pneumonia	(Lewinsohn et al., 1996; McIntosh et al., 1984)
4.	Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine.	SARS	(De Clercq, 2007)
5.	Nucleotide reverse transcriptase inhibitor: tenofovir disoproxil fumarate.	SARS	(De Clercq, 2007)
6.	Non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine and efavirenz.	SARS	De Clercq 2007
7.	Protease Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir and fosamprenavir.	SARS	De Clercq 2007
8.	Fusion inhibitor: enfuvirtide. Lamivudine and adefovir dipivoxil.	SARS	De Clercq 2007
9.	Umifenovir	ARVI, influenza, rhinovirus, adenovirus, parainfluenza, respiratory syncytial virus, coronavirus, including the causative agent of	(De Clercq, 2007)

	atypical pneumonia Used in the phase III trials of 2019- nCoV virus, SARS, MERS	
10. 3-chymotrypsin-like protease	SARS, MERS	(Chou et al., 2008; Kilianski et al., 2013; Li and De Clercq, 2020)
11. Papain-like protease	SARS, MERS and Human Coronavirus NL63.	(Chen, 2020; Harcourt et al., 2004; Kilianski et al., 2013)
12. RNA-dependent RNA polymerase	SARS, Murine Coronavirus.	(Imbert et al., 2006; Lu, 2020; Mahy et al., 1983)
13. Capsid spike glycoprotein (hCoV-EMC)	SARS, Human Coronavirus	(Gierer et al., 2013; Hoffmann et al., 2020; Howard et al., 2008)
14. Guanosine-analog RNA synthesis inhibitors	Coronavirus	(Beaucourt and Vignuzzi, 2014)
15. Nitazoxanide	SARS, MERS and Influenza	(Rossignol, 2016)
16. Influenza drugs	MERS	(De Clercq, 2007)
17. Remdesivir	COVID-19, SARS, MERS	Agostini et al. 2018; Wang 2020
18. Favipiravir	COVID-19	(Wang, 2020)
19. Darunavir	COVID-19	(Beck et al., 2020; Lin et al., 2020)
20. Lopinavir	COVID-19, SARS, MERS	Yao et al. 2020
21. Alcohol Vaporization or Nebulization Inhalation Therapy	COVID-19	(Cao, 2020)
22. Chloroquine	SARS, Human Coronavirus OC43.	(Keyaerts et al., 2009, 2004; Vincent et al., 2005)
23. ASC09	ARDS, Respiratory distress syndrome, SARS, MERS	(March and Bogatcheva, 2019, 2018)
24. TMPRSS2 inhibitor Camostat mesylate	SARS, MERS, Coronavirus 229E and COVID-19	(Bertram et al., 2013; Hoffmann et al., 2020; Kawase et al., 2012; Shirato et al., 2013)
25. Baricitinib	COVID-19	(Richardson et al., 2020; Stebbing et al., 2020)
26. Ruxolitinib	COVID-19	(Stebbing et al., 2020)

27. Saquinavir	SARS and Feline Coronavirus	(Blanchard et al., 2004; Comper, 2005; Hsieh et al., 2010)
28. Indinavir	SARS and COVID-19	(Contini, 2020; Tan et al., 2004)
29. Carfilzomib	COVID-19	(Wang, 2020)
30. Oseltamivir	COVID-19	(Haagmans et al., 2004; Lu, 2020)
31. Azvudine	COVID-19	(Hu et al., 2020)
32. Baloxavir marboxil	COVID-19	(Li and De Clercq, 2020)
33. Thymosin α 1	MERS	(Leyva-Grado and Behzadi, 2019)
34. Methylprednisolone	SARS, MERS	(Kim and Joh, 2006; Que et al., 2003)
35. Tocilizumab	COVID-19	(Diao et al., 2020)
36. Interferon Subtypes of β -1b, α -n1, α -n3, and human leukocyte interferon α	SARS	(Tan et al., 2004)
37. Acyclovir	SARS, MERS, Coronavirus 229E and COVID-19	(Peters et al., 2015)
38. Cathespin L	SARS	(Simmons et al., 2005)

Table 2 represents the commercially available drugs used for the treatment of the various forms of coronaviruses. The viral infections discussed in the table are SARS - Severe Acute Respiratory Syndrome, MERS - Middle East Respiratory Syndrome, RSV - Respiratory Syncytial Virus, ARVI - Acute respiratory viral infections

Table 3: Ongoing Clinical Trials for COVID – 19

S.No.	Study	Drug	Status	Organization
1.	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Sarilumab	Recruiting	Regeneron Study Site New York, New York, United States
2.	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	Remdesivir	Recruiting	1. Hoag Memorial Hospital Presbyterian Newport Beach, California, United States 2.Stanford Hospital, Stanford, California, United States 3. Providence Regional Medical Center Everett, Everett, Washington, United States
3.	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment	Remdesivir	Recruiting	1. Hoag Memorial Hospital Presbyterian Newport Beach, California, United States 2.Stanford Hospital, Stanford, California, United States 3. Providence Regional Medical Center Everett, Everett, Washington, United States
4.	Fingolimod in COVID-19	Fingolimod 0.5 mg	Recruiting	Wan-Jin Chen Fuzhou, China
5.	The Clinical Study of Carrimycin on Treatment Patients With COVID-19	1.Carrimycin 2. Lopinavir/ritonavir tablets or Arbidol or Chloroquine phosphate	Not yet recruiting	-
6.	Efficacy and Safety of Corticosteroids in COVID-19	Methylprednisolone	Recruiting	1. Hubei province hospital of integrated Chinese & Western Medicine Wuhan, Hubei, China 2. Yichang first people's Hospital Yichang, Hubei, China

7. Mild/Moderate 2019-nCoV Remdesivir RCT	Remdesivir	Recruiting	3. Renmin Hospital of Wuhan University Wuhan, China Jin Yin-tan hospital Wu Han, Hubei, China 1.National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section Bethesda, Maryland, United States 2. University of Nebraska Medical Center - Infectious Diseases Omaha, Nebraska, United States 3. University of Texas Medical Branch - Division of Infectious Disease Galveston, Texas, United States 4. Providence Sacred Heart Medical Center Spokane, Washington, United States Bin Cao Beijing, Beijing, China
8. Adaptive COVID-19 Treatment Trial	Remdesivir	Recruiting	
9. Severe 2019-nCoV Remdesivir RCT	Remdesivir	Recruiting	
10. Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.	Nitric Oxide Gas	Not yet recruiting	-
11. Efficacy and Safety of IFN- $\alpha 2\beta$ in the Treatment of Novel Coronavirus Patients Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection	Recombinant human interferon $\alpha 1\beta$	Not yet recruiting	-
12. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection	1.ASC09/ritonavir group 2. Lopinavir/ritonavir group	Not yet recruiting	-
13. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe	mRNA-1273	Not yet recruiting	Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases Seattle, Washington, United States Medical ICU,Peking Union Medical College Hospital
	Methylprednisolone	Recruiting	

	Acute Respiratory Failure			Beijing, Beijing, China
15.	Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment	1. Lopinavir/ritonavir 2. Ribavirin 3. Interferon Beta-1B	Recruiting	University of Hong Kong, Queen Mary Hospital Hong Kong, Hong Kong
16.	Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study	1. Chloroquine 2. Lopinavir/ Ritonavir	-	The Fifth Affiliated Hospital Sun Yat-Sen University
17.	A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases	Hydroxychloroquine	-	The Second Affiliated Hospital of Chongqing Medical University
18.	A prospective, randomized, open-label, parallel controlled trial for the preventive effect of hydroxychloroquine on medical personnel after exposure to COVID-19	Hydroxychloroquine	-	Renmin Hospital of Wuhan University
19.	The efficacy and safety of carrimycin treatment in patients with novel coronavirus infectious disease (COVID-19): a multicenter, randomized, open-label controlled trial	Carrimycin	-	Beijing You'an Hospital, Capital Medical University
20.	A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.	recombinant human interferon alpha 1b	-	Chinese PLA General Hospital
21.	A Pilot Study of Sildenafil in COVID-19	Sildenafil citrate	Recruiting	Department and Institute of Infectious Disease, Wuhan, Hubei, China
22.	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	1. Lopinavir/ritonavir 2. Hydroxychloroquine sulfate	Recruiting	Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Korea
23.	The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19	Thalidomide	Not yet recruiting	-
24.	Various Combination of Protease Inhibitors,	Oral	Not yet	Subsai Kongsangdao, Bangkok, Thailand

	Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial		recruiting	
25.	Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	Chloroquine	Not yet recruiting	-
26.	Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019	Favipiravir Combined with Tocilizumab	Recruiting	Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China Guiqiang Wang, Beijing, Beijing, China Peking University First Hospital, Beijing, Beijing, China
27.	Trial of Treatments for COVID-19 in Hospitalized Adults	1.Remdesivir 2.Lopinavir/ritonavir 3. Interferon Beta-1A	Not yet recruiting	-
28.	Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization	Losartan	Not yet recruiting	Hennepin County Medical Center, Minneapolis, Minnesota, United States M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States Hennepin County Medical Center, Minneapolis, Minnesota, United States
29.	Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization	Losartan	Not yet recruiting	M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States
30.	Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection	Ganovo with ritonavir +/- Interferon	Recruiting	The Ninth Hospital of Nanchang Nanchang, Jiangxi, China
31.	Eculizumab (Soliris) in Covid-19 Infected Patients	Eculizumab	Initiated	-

32. Expanded Access Remdesivir (RDV; GS-5734™)	Remdesivir	Initiated	-
33. Norwegian Coronavirus Disease 2019 Study	Hydroxychloroquine Sulfate	Not yet recruiting	-
34. Post-exposure Prophylaxis for SARS-Coronavirus-2	Hydroxychloroquine	Recruiting	University of Minnesota, Minneapolis, Minnesota, United States
35. The efficacy and safety of pirfenidone capsules in the treatment of severe new coronavirus pneumonia (COVID-19)	Pirfenidone	-	Third Xiangya Hospital of Central South University

The table represents a list of selected clinical trials for the amelioration of COVID – 19 specific drugs and vaccines.

Table 4: AYUSH recommended medicinal plant extracts for treating COVID-19
(Ref: AYUSH Ministry of Health Corona Advisory – D.O. No. S. 16030/18/2019 – NAM; dated: 06th March, 2020)

Indian Medicinal Plant	Form of extract	Trade Name	Indian Traditional Medical Practice	Preparation	Recommended Usage	Effective against
Preventive and Prophylactic						
<i>Tinospora cordifolia</i>	Aqueous	Samshamani Vati	Ayurveda	Samshamani Vati 500gm with warm water	Twice a day for 15 days	Chronic fever
<i>Andrograhis paniculata</i>	Aqueous	Nilavembu kudineer	Siddha	Nilavembu kudineer 60ml decoction	Twice a day for 14 days	Fever and cold
<i>Cydonia oblonga</i> <i>Zizyphus jujube</i> <i>Cordia myxa</i>	Aqueous	Behidana Unnab Sapistan	Unani	Behidana – 3gm Unnab – 5 Nos Sapistan – 9 Nos Boil these 3 in 250ml water, boil it until it remains half and filter it	Twice a day for 14 days	Antioxidant, immune-modulatory, anti-allergic, smooth muscle relaxant, anti-influenza activity
Arsenicum album 30	Tablet	Arsenicum album 30	Homeopathy	-	Daily once in empty stomach for 3 days (Should be repeated after 1 month till the infection persist).	Effective against SARS-CoV-2, immune-modulator.
Symptomatic Management for COVID-19						
AYUSH -64	Tablet	-	Ayurveda	-	2 tablets twice a day	Respiratory infections
Agastya Haritaki	Powder	Agasthya Rasayanam	Ayurveda	5gm in warm water	Twice a day	Upper respiratory infections
Anuthaila	Oil	Sesame oil	Ayurveda	-	2 drops in each nostril daily morning	Respiratory infections

Adathodai Manapagu	Aqueous	Adathodai Manapagu	Siddha	-	10ml twice a day	Fever
Bryonia alba	Tablet	Bryonia	Homeopathy	-	-	Reduce lung inflammation
Rhus toxico dendron	Tablet	Rhus tox	Homeopathy	-	-	Viral infections
<i>Atropa belladonna</i>	Tablet	Belladonna	Homeopathy	-	-	Asthma and chronic lung diseases
<i>Bignonia sempervirens</i>	Tablet	Gelsemium	Homeopathy	-	-	Asthma
<i>Eupatorium perfoliatum</i>	Tablet	Eupatorium perfoliatum	Homeopathy	-	-	Respiratory symptoms
Add on Interventions to the Conventional Care						
Vishasura kudineer	Tablet	Poly-herbal formulation	Siddha	Decoction 60ml	Twice a day	Fever
Kaba sura kudineer	Tablet	Poly-herbal formulation	Siddha	Decoction 60ml	Twice a day	Fever, cough, sore throat, shortness of breath

Table 4 depicts the Indian Medicinal plants and its usage provided by the AYUSH, Government of India as a therapeutic approach for COVID-19.

Table 5

[Click here to download Table: Table 5.docx](#)

Table 5: List of Indian medicinal herbs which might inhibit the HCoV and other Viruses

S.No	Plant Source	Mechanism of action	Target	Virus	Reference
1.	<i>Acacia nilotica</i>	Inhibition	-	HIV-PR	Mishra et al. 2014
2.	<i>Allium sativum</i>	Proteolytic and hemagglutinating activity and viral replication	-	SARS	Keyaerts et al. 2004
3.	<i>Andrographis paniculata</i>	Suppression	NLRP3, capase-1, and IL-1 β	SARS-COV and likely SARS-CoV-2	Liu et al. 2020
4.	<i>Boerhaavia diffusa</i>	Inhibition	ACE	-	Prathapan et al. 2013; Khan and Kumar 2019
5.	<i>Clerodendrum inerme Gaertn</i>	Inactivation	Ribosome	SARS-CoV-2	Olivieri et al. 1996
6.	<i>Clitoria ternatea</i>	Metalloproteinase inhibitor	ADAM17	-	Maity et al. 2012
7.	<i>Coriandrum sativum</i>	Inhibition	ACE	-	Pandey et al. 2011
8.	<i>Cynara scolymus</i> <i>Cassia occidentalis</i> <i>Coscinium fenestratum</i>	Inhibition	ACE	-	Prathapan et al. 2013; Khan and Kumar 2019
9.	<i>Embelia ribes</i>	Inhibition	ACE	-	Prathapan et al. 2013; Khan and Kumar 2019
10.	<i>Eugenia jambolana</i>	Inhibition	Protease	-	Otake et al. 1995
11.	<i>Euphorbia granulata</i>	Inhibition	-	HIV-1 PR	Mishra et al. 2014
12.	<i>Glycyrrhiza glabra</i>	Inhibition of viral replication; Modulation of membrane fluidity		SARS; HIV-1	Akamatsu et al. 1991; Cinatl et al. 2003; Fiore et al. 2008
13.	<i>Gymnema sylvestre</i>	Inhibition of viral DNA synthesis	-	-	Vimalanathan et al. 2009; Arun et al. 2014
14.	<i>Hyoscyamus niger</i>	Inhibition and Bronchodilator	Ca ²⁺	-	Gilani et al. 2008
15.	<i>Ocimum kilimandscharicum</i>	Inhibition	-	HIV-1	Thayil Seema and Thyagarajan 2016
16.	<i>Ocimum sanctum</i>	Inhibition	-	HIV-1	Rege and Chowdhary 2014
17.	<i>Punica granatum</i>	Inhibition	ACE	-	Prathapan et al. 2013; Khan and Kumar 2019
18.	<i>Salacia oblonga</i>	Suppression	angiotensin II, AT1 signal	-	He et al. 2011

19.	<i>Sambucus ebulus</i>	Inhibition	-	Enveloped virus	Ganjhu et al. 2015
20.	<i>Solanum nigrum</i>	-	-	HIV-1	Yu 2004
21.	<i>Sphaeranthus indicus</i>	Inhibition	-	Mouse corona virus and Herpes virus	Galani et al. 2010 Tiwari and Khosa 2009; Vimalanathan et al. 2009
22.	<i>Strobilanthes callosa</i>	Blocking	-	HCoV-NL63	Tsai et al., 2020 Tsai et al. 2020
23.	<i>Strobilanthes cusia</i>	Blocking	-	HCoV-NL63	Tsai et al., 2020 Tsai et al. 2020
24.	<i>Vitex negundo</i>	Inhibition	-	HIV-1	NAIR 2012
25.	<i>Vitex trifolia</i>	Reduction	-	SARS-COV	Liou et al. 2018

HIV- 1PR: Human Influenza Virus – 1 Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – Coronavirus; SARS-CoV-2: Severe Acute Respiratory Syndrome – Coronavirus 2; ACE – Angiotensin converting enzyme; HIV-1: Human Influenza Virus – 1; gp120: Envelope Glycoprotein 120; CD4: Cluster of Differentiation; HCoV-NL63: Human coronavirus NL63; RNA: Ribonucleic acid; MHV-A59: Mouse Hepatitis Virus –A59; CA2+: Calcium ion; NLRP3: NLR Family Pyrin Domain Containing 3; AT1: Angiotensin 1; HCoV-NL63: Human Coronavirus – NL63

Figure 1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)





Figure 3
[Click here to download high resolution image](#)



Structure and binding of COVID-19 virus to ACE2:

Fig.1: The above-mentioned figure depicts the structure of the COVID-19 virus. Among the viral structure the S protein has a major role in binding of the virus to the host receptor cells. S protein has two subunits which are the S1 receptor-binding subunit and S2 the membrane fusion subunit; where the earlier one attached itself to the ACE2 receptor of the human host cell and the S2 subunit internalises and creates the membrane fusion among the viral subunit and the ACE2 receptors. This leads to the release of the viral RNA into the host cell and results into respiratory infection.

Possible mechanism of action of SARS-COV-2

Fig.2: Depiction of the binding of SARS-COV-2 to its receptor ACE-2. The S1 and S2 subunits are subsequently cleaved followed by the shedding of ACE-2 by ADAM 17. This resulting in an increased amount of Angiotensin II leading to respiratory distress. Upon binding, the virus fuses with the membrane and enters the cell, followed by translation, and replication of the proteins. ORF3a, ORF8b,E proteins and the NF-KB pathway activates the inflammasome pathway through various means, leading to the activation of cytokine. This results in a cytokine storm, further resulting in respiratory distress.

COVID-19 entry into CNS

Fig.3: Entry of human Coronavirus in CNS through olfactory bulb upon nasal infection which causes inflammation and demyelination. Further it reaches the whole brain via Blood Brain Barrier and CSF via Blood- CSF barrier in < 7 days. The possible entry of SARS-CoV-2 into the Brain and CNS is important to design effective antiviral drugs. Effective drugs that may cross Blood Brain Barrier and Blood CSF barrier may be taken in to consideration while designing and this could be a promising in treatment strategies.